<SEC-DOCUMENT>0001140361-24-028205.txt : 20240530
<SEC-HEADER>0001140361-24-028205.hdr.sgml : 20240530
<ACCEPTANCE-DATETIME>20240530173249
ACCESSION NUMBER:		0001140361-24-028205
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240529
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240530
DATE AS OF CHANGE:		20240530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		241006805

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20029730x2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:insm="http://insmed.com/20240529" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_c8dda05d303c4b779810a738c71c9361" contextRef="c20240529to20240529" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_de04b2cd7eda43e5957508693291fcc5" contextRef="c20240529to20240529">0001104506</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="insm-20240529.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240529to20240529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
<div>UNITED STATES</div>
</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_eae7af90ccef4de6b9fc813a666f75d5" contextRef="c20240529to20240529">8-K</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">The Securities Exchange Act of 1934</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_5253ef384f724a11833ad67cc37b3491" contextRef="c20240529to20240529" format="ixt:date-monthname-day-year-en">May 29, 2024</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_33384b1a15c94797a165d1d61baeb201" contextRef="c20240529to20240529">INSMED INCORPORATED</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Exact name of registrant as specified in its charter)</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_764567eb4bac4d22a41cf6e79c04d22f" contextRef="c20240529to20240529" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric></div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_479c213e4fb64cf989e8c030be0f9f59" contextRef="c20240529to20240529">000-30739</ix:nonNumeric></div>
          </td>

    <td style="width: 33.34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_eaf62598e30040a3b31def86ccaed95d" contextRef="c20240529to20240529">54-1972729</ix:nonNumeric></div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(State or other jurisdiction</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Commission</div>
          </td>

    <td style="width: 33.34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(IRS Employer</div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">File Number)</div>
          </td>

    <td style="width: 33.34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 67.34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_304ae780e41b46c78f1709c138914032" contextRef="c20240529to20240529">700 US Highway 202/206</ix:nonNumeric><br/>
            </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_f5662e85d14e40ebb636a9fda667489b" contextRef="c20240529to20240529">Bridgewater</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_47da7fabba374f9da8d2c6a142d6086e" contextRef="c20240529to20240529" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></div>
          </td>

    <td style="width: 32.66%; vertical-align: bottom; text-align: center;">
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_e26b09d7cee4496286fae9e011b89948" contextRef="c20240529to20240529">08807</ix:nonNumeric></div>
          </td>

  </tr>

  <tr>

    <td style="width: 67.34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 32.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_b297373456414a0dad9df941da58dfee" contextRef="c20240529to20240529">908</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_ab67c0cb465c436b96230368a22140ef" contextRef="c20240529to20240529">977-9900</ix:nonNumeric></span></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Not Applicable</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Former name or former address, if changed since last report.)</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions (see General Instruction A.2. below):</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_53d49ec961ec4869b7317396708aea19" contextRef="c20240529to20240529" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Written communications pursuant to Rule
      425 under the Securities Act (17 CFR 230.425)</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_e0e1678cfd89425394a5c5cc88306f6b" contextRef="c20240529to20240529" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule
      14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_757f68c5b374477a9c977602de2cee53" contextRef="c20240529to20240529" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant
      to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_2a79e5018113423ebdd403ab96e9d660" contextRef="c20240529to20240529" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant
      to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 37.64%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 24.83%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Trading Symbol(s)</div>
          </td>

    <td style="width: 37.54%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 37.64%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_b44f21f76eee41db9260f6bbadbeff0f" contextRef="c20240529to20240529">Common Stock, par value $0.01 per share</ix:nonNumeric></div>
          </td>

    <td style="width: 24.83%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_c17e9219d6664984a715939b46221d49" contextRef="c20240529to20240529">INSM</ix:nonNumeric></div>
          </td>

    <td style="width: 37.54%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_f87e91fe3f9842a4a1cdd8ce052ef785" contextRef="c20240529to20240529" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule
      12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_6cabafac55704fcf82f9816de9e91a1b" contextRef="c20240529to20240529" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;
      </div>
<hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div><br/>
    </div>

    <div><span style="font-weight: bold;">ITEM 8.01 &#8212; Other Events. </span></div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 29, 2024, Insmed Incorporated (the &#8220;Company&#8221;) entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Goldman Sachs &amp; Co. LLC
      and Leerink Partners LLC as representatives of the several underwriters (the &#8220;Underwriters&#8221;), pursuant to which, subject to satisfaction of the conditions set forth therein, the Company has agreed to sell to the Underwriters, and the Underwriters
      have agreed to purchase from the Company, 12,621,359 shares (the &#8220;Firm Shares&#8221;) of the common stock, par value $0.01 per share, of the Company (the &#8220;Common Stock&#8221;). The Company also granted the Underwriters a 30-day option to purchase up to an
      additional 1,893,203 shares of Common Stock (together with the Firm Shares, the &#8220;Shares&#8221;), which the Underwriters exercised in full on May 30, 2024. The Underwriters will purchase the Shares from the Company at a price, after underwriting discounts
      and commissions, of $49.1825 per share, resulting in net proceeds to the Company before other estimated offering expenses payable by the Company of approximately $713.9 million.</div>

    <div><br/>
    </div>
<div>
    The offering of the Shares (the &#8220;Offering&#8221;) is being made pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration Statement No. 333-272088) that became automatically effective upon filing with the Securities and Exchange
    Commission (the &#8220;SEC&#8221;) on May 19, 2023, which includes a base prospectus dated May 19, 2023 (the &#8220;Registration Statement&#8221;), as supplemented by a preliminary prospectus supplement filed with the SEC on May 29, 2024, and a final prospectus supplement
    dated May 29, 2024 and filed with the SEC on May 30, 2024.
    </div>
<div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company made certain customary representations, warranties and covenants in the Underwriting Agreement concerning the Company, the Registration Statement
      and the Offering. The Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company and the Underwriters expect to consummate the
      sale and purchase of the Firm Shares pursuant to the Underwriting Agreement on May 31, 2024, subject to the satisfaction of customary closing conditions.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing
      description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The legal opinion of Hunton Andrews Kurth LLP relating to the Shares is filed herewith as Exhibit 5.1.</div>

    <div><br/>
    </div>

    <div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 7.01 &#8212; Regulation FD Disclosure.</div>

        <div><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 28, 2024, the Company issued a press release announcing the commencement of the Offering. On May 30, 2024, the Company issued a press release
          announcing the pricing of the Offering. Copies of the press releases are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.</div>

        <div><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information contained in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of
          the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</div>

      </div>

      <div><br/></div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 9.01 - Financial Statements and Exhibits.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Exhibits</span></span></div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">No.</div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20029730x2_ex1-1.htm">1.1</a></div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Underwriting Agreement, dated May <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">29, 2024, by and among Insmed
                Incorporated, Goldman Sachs &amp; Co. LLC and Leerink Partners LLC., as representatives of the several underwriters named therein.</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20029730x2_ex5-1.htm">5.1</a></div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opinion of Hunton Andrews Kurth LLP related to the Shares.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20029730x2_ex5-1.htm">23.1</a></div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consent of Hunton Andrews Kurth LLP (included in Exhibit 5.1).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20029730x2_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press release issued by Insmed Incorporated on May 28, 2024.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20029730x2_ex99-2.htm">99.2</a></div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press release issued by Insmed Incorporated on May 30, 2024.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
          </td>

    <td style="width: 1.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Date File (embedded within the Inline XBRL document)</div>
          </td>

  </tr>


</table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">SIGNATURES</span></div>

    <div><br/>
    </div>

    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned hereunto duly authorized.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 59.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: May 30, 2024</div>
          </td>

    <td style="vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">INSMED INCORPORATED</div>
          </td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top;">&#160;</td>

    <td style="width: 4%; vertical-align: top;">&#160;</td>

    <td style="width: 36%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top;">&#160;</td>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 36%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Michael A. Smith<br/>
          </td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top;">&#160;</td>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
          </td>

    <td style="width: 36%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michael A. Smith</div>
          </td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top;">&#160;</td>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
          </td>

    <td style="width: 36%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Legal Officer and Corporate Secretary</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ny20029730x2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <div style="text-align: right;"><font style="font-weight: bold;"> </font>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: right;"><font style="font-weight: bold;"> Exhibit 1.1</font><br>
    </div>
    <div> <br>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold; font-style: italic;">EXECUTION VERSION</font><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">INSMED INCORPORATED</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Common Stock, Par Value $0.01 Per Share</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Underwriting Agreement</u></div>
    <div>&#160;</div>
    <div style="text-align: right; text-indent: -54pt; margin-left: 405pt; font-family: 'Times New Roman',Times,serif;">May 29, 2024</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div>Goldman Sachs &amp; Co. LLC</div>
    <div>Leerink Partners LLC</div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;">As representatives (the &#8220;Representatives&#8221;) of the several Underwriters named in Schedule I hereto,</div>
    <div style="text-indent: 36pt;"> <br>
    </div>
    <div>c/o Goldman Sachs &amp; Co. LLC</div>
    <div>200 West Street,</div>
    <div>New York, New York 10282</div>
    <div>&#160;</div>
    <div>c/o Leerink Partners LLC</div>
    <div>53 State Street, 40<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
    <div>Boston, Massachusetts 02109</div>
    <div>&#160;</div>
    <div>Ladies and Gentlemen:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Insmed Incorporated, a Virginia corporation (the &#8220;Company&#8221;), proposes, subject to the terms and conditions stated in this agreement (this &#8220;Agreement&#8221;), to issue and sell to the underwriters named in
      Schedule I hereto (the &#8220;Underwriters&#8221;) an aggregate of 12,621,359 shares<font style="font-weight: bold;">&#160;</font>(the &#8220;Firm Securities&#8221;) and, at the election of the Underwriters, up to 1,893,203 additional shares (the &#8220;Optional Securities&#8221;) of shares
      of common stock, par value $0.01 per share (&#8220;Stock&#8221;) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the &#8220;Securities&#8221;).</div>
    <div>&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The Company has filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) an automatic shelf registration statement, including a prospectus, on Form S-3 (File No. 333-272088) relating to
      securities (the &#8220;Shelf Securities&#8221;), including the Securities, to be issued from time to time by the Company, which automatic shelf registration statement became effective under Rule 462(e) under the Securities Act of 1933, as amended (the &#8220;Act&#8221;).
      Such registration statement including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A or Rule 430B under the Act is hereinafter referred to as the &#8220;Registration Statement&#8221;,
      and the related prospectus covering the Shelf Securities dated May 19, 2023 in the form first used to confirm sales of the Securities (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to
      Rule 173 under the Act) is hereinafter referred to as the &#8220;Basic Prospectus&#8221; and any preliminary prospectus (including any preliminary prospectus supplement) relating to the Securities filed with the Commission pursuant to Rule 424(b) under the Act
      is hereinafter called a &#8220;Preliminary Prospectus.&#8221; The Basic Prospectus, as supplemented by the prospectus supplement specifically relating to the Securities in the form first used to confirm sales of the Securities (or in the form first made
      available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 of the Act) is hereinafter referred to as the &#8220;Prospectus.&#8221;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%-%-%-->
    <div style="text-align: justify; text-indent: 36pt;">For purposes of this Agreement, &#8220;free writing prospectus&#8221; has the meaning set forth in Rule 405 under the Act, &#8220;Time of Sale Prospectus&#8221; means the documents and pricing information set forth in
      Schedule II hereto, and &#8220;broadly available road show&#8221; means a &#8220;bona fide electronic road show&#8221; as defined in Rule 433(h)(5) under the Act that has been made available without restriction to any person. As used herein, the terms Registration
      Statement, Basic Prospectus, Time of Sale Prospectus and Prospectus shall include the documents, if any, incorporated by reference therein. The terms &#8220;supplement,&#8221; &#8220;amendment,&#8221; and &#8220;amend&#8221; as used herein with respect to the Registration Statement,
      the Basic Prospectus, the Time of Sale Prospectus or any free writing prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that
      are deemed to be incorporated by reference therein; any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company filed pursuant to Section 13(a) or 15(d) of the Exchange Act
      after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement; any oral or written communication with potential investors undertaken in reliance on Rule 163B under the Act is hereinafter called
      a &#8220;Testing-the-Waters Communication&#8221;; and any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Act is hereinafter called a &#8220;Written Testing-the-Waters Communication&#8221;; and any &#8220;issuer free
      writing prospectus&#8221; as defined in Rule 433 under the Act relating to the Securities is hereinafter called an &#8220;Issuer Free Writing Prospectus&#8221;.</div>
    <div>&#160;</div>
    <div>
      <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif;">The Company represents and warrants to, and agrees with, each of the Underwriters that:</font></div>
      <div style="text-align: justify;"> <br>
        <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(a)&#160; The Registration Statement became effective upon filing; the filing date of the Registration Statement was not earlier than the date three years before the execution date of this
          Agreement; and no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by, the Commission.&#160; (i) At the time of
          filing the Registration Statement, (ii) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to
          Sections 13 or 15(d) of the Exchange Act or form of prospectus), (iii) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c)) made any offer relating to the Securities in reliance on
          the exemption in Rule 163, and (iv) as of the date hereof, the Company was or is, as applicable, a &#8220;well-known seasoned issuer&#8221; (as defined in Rule 405 under the Act) eligible to use the Registration Statement as an automatic shelf registration
          statement and the Company has not received notice that the Commission objects to the use of the Registration Statement as an automatic shelf registration statement.</div>
        <div style="font-family: 'Times New Roman',Times,serif; margin-left: 36pt;"> <br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0pt;">
          <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(b)&#160; (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or the Prospectus complied or will comply
            when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii) each part of the Registration Statement, when such part became effective, did not contain, and each such
            part, as amended or supplemented, if applicable, as of the First Time of Delivery and as of any additional Time of Delivery (each as defined in Section 4(a)) will not contain any untrue statement of a material fact or omit to state a material
            fact required to be stated therein or necessary to make the statements therein not misleading, (iii) the Registration Statement, as of the date hereof, does not and, as of the first Time of Delivery and as of any additional Time of Delivery,
            will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv) the Registration Statement and the Prospectus comply, and
            as amended or supplemented, if applicable, will comply in all material respects with the Act and the applicable rules and regulations of the Commission thereunder, (v) the Time of Sale Prospectus does not, and at the time of each sale of the
            Securities in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the First Time of Delivery and as of any additional Time of Delivery, the Time of Sale Prospectus, as then amended or
            supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not
            misleading, (vi) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not and will not as of the First Time of Delivery and as of any additional Time of Delivery contain any untrue statement
            of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (vii) the Prospectus as of the date hereof does not contain and, as
            amended or supplemented, if applicable, as of the First Time of Delivery and as of any additional Time of Delivery will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
            therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of
            Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter expressly for use therein.</div>
          <div style="font-family: 'Times New Roman', Times, serif;"> <br>
          </div>
          <div style="font-family: 'Times New Roman', Times, serif;">
            <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(c)&#160; (i) At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a <font style="font-style: italic;">bona fide</font>
              offer (within the meaning of Rule 164(h)(2)) of the Securities and (ii) as of the date hereof, the Company is not an &#8220;ineligible issuer&#8221; in connection with the offering pursuant to Rules 164, 405 and 433 under the Act. Any free writing
              prospectus that the Company is required to file pursuant to Rule 433(d) under the Act has been, or will be, filed with the Commission in accordance with the requirements of the Act and the applicable rules and regulations of the Commission
              thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Act or that was prepared by or on behalf of or used or referred to by the Company (x) complies or will comply in
              all material respects with the requirements of the Act and the applicable rules and regulations of the Commission thereunder and (y) does not include any information that conflicts with the information contained in the Registration Statement,
              including any document incorporated therein by reference and any prospectus supplement deemed to be a part thereof that has not been superseded or modified. Except for the free writing prospectuses, if any, identified in Schedule II hereto
              forming part of the Time of Sale Prospectus, and electronic road shows, if any, each furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any
              free writing prospectus.</div>
            <div><br>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(d)&#160; There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the
                earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus.<br>
              </div>
              <div style="font-family: 'Times New Roman',Times,serif;"> <br>
              </div>
              <div>
                <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(e)&#160; The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power
                  and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its
                  ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing could not reasonably be expected, individually or in the aggregate, to have a material adverse
                  effect on the Company and its subsidiaries, taken as a whole.</div>
                <div> <br>
                </div>
                <div>
                  <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(f)&#160; The Company&#8217;s only subsidiaries are as listed in Schedule III hereto.</div>
                  <div> <br>
                  </div>
                  <div>
                    <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(g)&#160; This Agreement has been duly authorized, executed and delivered by the Company.</div>
                    <div> <br>
                    </div>
                    <div>
                      <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(h)&#160; The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Time of Sale Prospectus and the Prospectus.</div>
                      <div> <br>
                      </div>
                      <div>
                        <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(i)&#160; The shares of Stock outstanding prior to the issuance of the Securities have been duly authorized and are validly issued, fully paid and non-assessable.</div>
                        <div> <br>
                        </div>
                        <div>
                          <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(j)&#160; The Securities have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and
                            non-assessable, and the issuance of such Securities will not be subject to any preemptive or similar rights, which have not otherwise been waived.</div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                <div class="BRPFPageBreak" style="page-break-after: always;">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(k)&#160; The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene any provision of (i) applicable law,
                (ii) the articles of incorporation or bylaws of the Company, (iii) any agreement or other instrument binding upon the Company or any of its subsidiaries or (iv) any judgment, order or decree of any governmental body, agency or court having
                jurisdiction over the Company or any subsidiary, except in the cases of clauses (i), (iii) and (iv) for any such contravention that would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries
                taken as a whole, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may be
                required under the Act or the rules and regulations thereunder or by the securities or Blue Sky laws of the various states or the rules and regulations of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) in connection with the offer
                and sale of the Securities.</div>
              <div> <br>
              </div>
              <div>
                <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(l)&#160; There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its subsidiaries is a party or to which
                  any of the properties of the Company or any of its subsidiaries is subject other than (i) proceedings accurately described in all material respects in the Time of Sale Prospectus or (ii) proceedings that would not reasonably be expected
                  to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time
                  of Sale Prospectus; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are
                  not described or filed as required.</div>
                <div> <br>
                </div>
                <div>
                  <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(m)&#160; The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for
                    in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</div>
                  <div> <br>
                  </div>
                  <div>
                    <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(n)&#160; The Company is not, and after giving effect to the offering and sale of the Securities to be sold by the Company and the application of the proceeds thereof as described in
                      the Prospectus will not be, required to be registered as an &#8220;investment company&#8221; as such term is defined in the Investment Company Act of 1940, as amended.</div>
                    <div> <br>
                    </div>
                    <div>
                      <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(o)&#160; The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of
                        human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#8220;Environmental Laws&#8221;), (ii) have received all permits, licenses or other approvals required of them under applicable
                        Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive
                        required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the Company and its
                        subsidiaries, taken as a whole.</div>
                      <div> <br>
                      </div>
                      <div>
                        <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(p)&#160; To the Company&#8217;s knowledge, there are no facts currently existing that will require the Company or any of its subsidiaries to incur costs or liabilities associated with
                          Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related
                          constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
                        <div> <br>
                        </div>
                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                          <div class="BRPFPageBreak" style="page-break-after: always;">
                            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                        </div>
                        <div>
                          <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(q)&#160; Except as disclosed in the Time of Sale Prospectus and the Prospectus, none of the Company nor any of its subsidiaries is or, since January 1, 2022 has been, in
                            violation of any Health Care Laws, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries taken
                            as a whole. For purposes of this Agreement, &#8220;Health Care Laws&#8221; means, to the extent applicable to the Company, (i) the Federal Food, Drug, and Cosmetic Act, and the regulations promulgated thereunder, (ii) all federal and state
                            fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b(b)), the Stark Law (42 U.S.C. &#167;1395nn), the Civil False Claims Act (31 U.S.C. &#167;3729 et seq.), Sections 1320a-7 and
                            1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes, (iii) the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (18
                            U.S.C. &#167;&#167;669, 1035, 1347 and 1518; 42 U.S.C. &#167;1320d et seq.) and the regulations promulgated thereunder, (iv) Titles XVIII (42 U.S.C. &#167;1395 et seq.) and XIX (42 U.S.C. &#167;1396 et seq.) of the Social Security Act and the
                            regulations promulgated thereunder, (v) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (42 U.S.C. &#167;1395w-101 et seq.) and the regulations promulgated thereunder, (vi) the so-called federal &#8220;Sunshine
                            Law&#8221; or Open Payments (42 U.S.C. &#167;1320a-7h) and state or local laws regulating or requiring reporting of interactions between pharmaceutical manufacturers and members of the healthcare industry and regulations promulgated
                            thereunder, (vii) laws governing government pricing or price reporting programs and regulations promulgated thereunder, including without limitation the Medicaid Drug Rebate Program (42 U.S.C. &#167; 1396r-8) and any state
                            supplemental rebate program, the Public Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126) or any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement,
                            and any successor government programs, (viii) all statutes, rules or regulations of applicable governmental authorities applicable to the ownership, testing, research, development, manufacture, quality, safety, accreditation,
                            packaging, storage, use, distribution, labeling, promotion, sale, offer for sale, import, export or disposal of any product manufactured or distributed by the Company or its subsidiaries, including current good manufacturing
                            practices requirements; and (ix) any and all other health care laws and regulations applicable to&#160; the Company or its subsidiaries or their respective businesses, each as currently conducted, as described in the Time of Sale
                            Prospectus, each of (i) through (ix) as may be amended from time to time.</div>
                          <div> <br>
                          </div>
                          <div>
                            <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(r)&#160; Neither the Company nor any of its subsidiaries has received written notice of any pending or threatened claim, suit, proceeding, hearing, enforcement, audit,
                              investigation, arbitration or other legal action that has not been resolved from any applicable governmental authority or any third party, including employees, former employees or competitors, alleging that any operation or
                              activity of the Company or any of its subsidiaries is in violation of any applicable Health Care Laws, except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on the
                              Company and its subsidiaries taken as a whole.&#160; Except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries taken as a whole, (i) the
                              Company and its subsidiaries have timely submitted all registrations or other filings required under any applicable Health Care Laws with governmental authorities, (ii) and those filings have, to the knowledge of the Company,
                              been complete and accurate when filed or corrected as appropriate by the Company if subsequently determined not to be complete or to be inaccurate.</div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div><br>
            </div>
            <div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(s)&#160; Except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries taken as a whole, the Company:
                (i) has in place current agreements for its marketed product to participate in Federal Health Care Programs; and (ii) is in compliance with all such agreements including, without limitation, provisions in such agreements pertaining to the
                timely and current submission of accurate prices to federal and state agencies.&#160; For purposes of this Agreement, &#8220;Federal Health Care Program&#8221; has the meaning set forth in 42 U.S.C. 1320a-7b(f).</div>
              <div> <br>
              </div>
              <div>
                <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(t)&#160; The Company and its subsidiaries have an operational healthcare compliance program that: (i) governs all employees and contractors, including sales representatives; (ii) is
                  materially consistent with the current U.S. Federal Sentencing Guidelines standards for effective compliance programs and U.S. Department of Health and Human Services Office of Inspector General Voluntary Compliance Guidance for
                  Pharmaceutical Manufacturers; (iii) complies with the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals; and (iv) addresses compliance with Health Care Laws.&#160; The Company and each of
                  its subsidiaries operates in material compliance with such healthcare compliance program.</div>
              </div>
            </div>
            <div>
              <div> <br>
              </div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(u)&#160; Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders or similar agreements
                with or imposed by any governmental authority.</div>
            </div>
            <div><br>
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(v)&#160; None of the Company, its subsidiaries, or any of their respective officers, directors, or employees, or to the knowledge of the Company, any independent contractor, is excluded,
                suspended or debarred from participation in any Federal Health Care Program or human research study or clinical trial or, to the knowledge of the Company, is or has been the subject of a governmental inquiry, investigation, proceeding or
                other action, including a criminal conviction or imposition of a civil monetary penalty, that would reasonably be expected to result in debarment, suspension, or exclusion. The Company periodically conducts screening of officers, directors,
                employees and independent contractors to confirm such persons are not excluded, suspended or debarred from participation in any Federal Health Care Program or human research study or clinical trial.</div>
              <div> <br>
              </div>
              <div>
                <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(w)&#160; Except as described in the Time of Sale Prospectus and the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such
                  person the right to require the Company to file a registration statement under the Act with respect to any securities of the Company or to require the Company to include such securities with the Securities registered pursuant to the
                  Registration Statement.</div>
                <div> <br>
                </div>
                <div>
                  <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(x)&#160; Neither the Company nor any of its subsidiaries or affiliates, nor any director or officer, nor to the knowledge of the Company, any employee, agent or representative of the
                    Company or of any of its subsidiaries or affiliates, has taken any action (i) in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating
                    Bribery of Foreign Public Officials in International Business Transactions, and the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law (collectively &#8220;Anti-Corruption Laws&#8221;), or (ii) in
                    furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving or receiving of money, property, gifts or anything else of value (including nonmonetary benefits such as employment opportunities,
                    gifts, travel, or entertainment), directly or indirectly, to any &#8220;government official&#8221; (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person
                    acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) or any other person to improperly influence official action, to improperly gain or
                    retain business, or secure an improper advantage for the benefit of the Company. The Company and its subsidiaries have conducted their businesses in compliance in all material respects with the Anti-Corruption Laws, and the Company and
                    its subsidiaries will not knowingly, directly or indirectly, use the proceeds of the offering and sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate, agent, partner or
                    other person or entity, for the purpose of financing or facilitating any activity that would violate any of the Anti-Corruption Laws.</div>
                </div>
              </div>
            </div>
            <div><br>
            </div>
            <div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(y)&#160; The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements,
                including, without limitation, those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, and the applicable
                anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by
                any governmental agency where the Company and its subsidiaries conduct business (collectively, the &#8220;Anti-Money Laundering Laws&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
                arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</div>
            </div>
            <div><br>
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(z)&#160; Neither the Company nor any of its subsidiaries or, any director, officer, or to the knowledge of the Company, any employee, agent, affiliate or representative of the Company or
                any of its subsidiaries, is an individual or entity (&#8220;Person&#8221;) that is, or is owned or controlled by a Person that is: (i) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets
                Control (and including, without limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury or other relevant sanctions authority
                (collectively, &#8220;Sanctions&#8221;), nor (ii) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Cuba, Iran, North Korea, Syria, the Crimea Region of Ukraine, the so-called
                Donetsk People&#8217;s Republic, the so-called Luhansk People&#8217;s Republic, or any other Covered Region of Ukraine identified pursuant to Executive Order 14065).&#160; For the past five years, the Company has not knowingly engaged in and is not now
                knowingly engaged in any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</div>
              <div> <br>
              </div>
              <div>
                <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(aa)&#160; Subsequent to the respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i) the Company and
                  its subsidiaries have not incurred any material liability or obligation, direct or contingent, and have not entered into any material transactions, in each case, that would be required to be reported on a Current Report on Form 8-K; (ii)
                  the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock, nor declared, paid or otherwise made any dividend or distribution of
                  any kind on its capital stock other than ordinary and customary dividends and net settlements in connection with the Company&#8217;s existing employee compensation plans; and (iii) there has not been any material change in the capital stock,
                  short-term debt or long-term debt of the Company and its subsidiaries, except in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively, or except for a change in the
                  number of outstanding shares of common stock of the Company due to the issuance of shares upon the exercise of currently outstanding options or other stock-based awards or the vesting of restricted stock units under (i) the Company&#8217;s
                  Amended and Restated 2000 Stock Incentive Plan (the &#8220;2000 Plan&#8221;), 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 2015 Incentive Plan (the &#8220;2015 Plan&#8221;), 2017 Incentive Plan (the &#8220;2017 Plan&#8221;) and the Amended and Restated 2019 Incentive Plan, as
                  amended (the &#8220;2019 Plan&#8221;) or (ii) inducement grants previously made to new employees.</div>
                <div> <br>
                </div>
                <div>
                  <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(bb)&#160; The Company and its subsidiaries do not own any real property. The Company and its subsidiaries have good title to all personal property owned by them which is material to
                    the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do not materially affect the value of such
                    property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any material real property and buildings held under lease by the Company and its subsidiaries are held by
                    them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case
                    except as described in the Time of Sale Prospectus.</div>
                  <div> <br>
                  </div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div>
                    <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(cc)&#160; Except as described in the Time of Sale Prospectus, (A) the Company and its subsidiaries own or possess, or can acquire on reasonable terms, all material patents, patent
                      rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and other
                      intellectual property (collectively, &#8220;Intellectual Property&#8221;) currently used and proposed to be used by them in connection with the Company&#8217;s business as now conducted and as described in the Time of Sale Prospectus, and (B) neither
                      the Company nor any of its subsidiaries has breached any material provision of any Intellectual Property license or received any notice of infringement of or conflict with asserted rights of others with respect to any of the
                      foregoing, in the case of each of (A) and (B), which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse effect on the Company and its
                      subsidiaries, taken as a whole. There are no valid and enforceable rights of third parties to any Intellectual Property that are or would be infringed by the business currently conducted or planned to be conducted by the Company and
                      its subsidiaries or in the manufacture, use, sale or offer for sale of its presently proposed products, as such planned business and proposed products are described in the Time of Sale Prospectus which infringement, singly or in the
                      aggregate, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. There are no pending patent applications of which the Company is aware, which, if granted in current
                      form, would be infringed by the business currently conducted by it or proposed to be conducted by it as described in the Time of Sale Prospectus, which infringement, singly or in the aggregate, would reasonably be expected to have a
                      material adverse effect on the Company and its subsidiaries, taken as a whole. Neither the Company, nor any of its subsidiaries, is subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local,
                      foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any contract, in the case of each of the foregoing,
                      which materially restricts or impairs its use of any Intellectual Property and which restriction or impairment, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its
                      subsidiaries, taken as a whole.&#160; To the knowledge of the Company, there are no ongoing infringements by others of any Intellectual Property owned by the Company or its subsidiaries in connection with the business currently conducted
                      by the Company and its subsidiaries or its presently proposed products, as described in the Time of Sale Prospectus, which infringement, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the
                      Company and its subsidiaries, taken as a whole. The Company is not aware of any reason why any Intellectual Property owned or controlled by it is or should be held to be invalid or unenforceable, which holding, singly or in the
                      aggregate, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
                    <div> <br>
                    </div>
                    <div>
                      <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(dd)&#160; Except as described in the Time of Sale Prospectus, no material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of
                        the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could have a material adverse
                        effect on the Company and its subsidiaries, taken as a whole.</div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <br>
          </div>
        </div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; margin-left: 0pt;">
        <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(ee)&#160; The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent in the
          reasonable opinion of the Company&#8217;s management and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company nor
          any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain comparable coverage from similar insurers as may be necessary to continue its
          business at a cost that would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus.</div>
        <div style="font-family: 'Times New Roman', Times, serif;"> <br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="font-family: 'Times New Roman', Times, serif;">
          <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(ff)&#160; The Company and its subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary
            to conduct their respective businesses in the manner described in the Time of Sale Prospectus, including, without limitation, (i) all U.S. Food and Drug Administration (the &#8220;FDA&#8221;) clearances or approvals necessary to conduct the Company&#8217;s
            business as now conducted and (ii) applicable foreign regulatory agency clearances, permits or approvals necessary to conduct the Company&#8217;s business as now conducted. Neither the Company nor any of its subsidiaries has received any notice of
            proceedings relating to the revocation or modification of any such certificate, authorization or permit, including, without limitation, any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or
            notice from the FDA, any other governmental or regulatory authority or any third party which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse
            effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus.</div>
          <div> <br>
          </div>
          <div>
            <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(gg)&#160; The Company and each of its subsidiaries have operated their businesses and currently are in compliance in all material respects with all applicable rules, regulations and
              policies of the FDA and any applicable comparable foreign regulatory organization, including, without limitation, all applicable directives and regulations of the European Medicines Agency. The Company has not received notice of any claim,
              action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or
              activity is in material violation of any applicable laws or material certificates, authorizations or permits and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party
              is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding. </div>
            <div> <br>
            </div>
            <div>
              <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(hh)&#160; The description of the results of the studies, tests and trials conducted by or on behalf of the Company contained in the Time of Sale Prospectus and the Prospectus are accurate
                in all material respects and the Company has no knowledge of any other studies, tests or trials, the results of which are materially inconsistent with the results described in the Time of Sale Prospectus and the Prospectus.</div>
              <div> <br>
              </div>
              <div>
                <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(ii)&#160; Any clinical trials or human and animal studies conducted by or on behalf of the Company and described in the Time of Sale Prospectus were and, if still pending, are being
                  conducted (to the Company&#8217;s knowledge, after due inquiry, with respect to such studies conducted by third parties) in accordance, in all material respects, with standard medical and scientific research procedures, the Federal Food, Drug
                  and Cosmetic Act and the rules and regulations promulgated thereunder, and all applicable rules, regulations and policies of the FDA, including, where applicable, current good clinical practices and Good Laboratory Practices, as such
                  terms are understood in the Company&#8217;s industry, and all applicable foreign regulatory requirements and standards. Except as described in the Time of Sale Prospectus or the Registration Statement, the Company has not received any notices
                  or correspondence from the FDA or any other governmental authority contemplating or requiring the termination, suspension or modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company,
                  other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies, trials and tests, none of which modifications would have a material impact on such study, trial or
                  test.</div>
                <div> <br>
                </div>
                <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div class="BRPFPageBreak" style="page-break-after: always;">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>
                  <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(jj)&#160; Except as described in the Time of Sale Prospectus or the Registration Statement, the Company and each of its subsidiaries maintain a system of internal accounting controls
                    sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements
                    in conformity with generally accepted accounting principles as applied in the United States (&#8220;U.S. GAAP&#8221;) and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific
                    authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Time of Sale
                    Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (A) no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (B) no change in the
                    Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</div>
                  <div> <br>
                  </div>
                  <div>
                    <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(kk)&#160; Except as described in the Time of Sale Prospectus or the Registration Statement, the Company has not sold, issued or distributed any shares of Stock during the six-month
                      period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other compensation or
                      incentive plans or pursuant to the exercise or vesting of, as applicable, outstanding options, restricted stock units, other stock-based awards or inducement grants made to new employee hires.</div>
                    <div> <br>
                    </div>
                    <div>
                      <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(ll)&#160; The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases
                        (collectively, &#8220;IT Systems&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted.&#160; The Company
                        and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards designed to maintain and protect their material confidential information and the integrity, continuous
                        operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#8220;Personal Data&#8221;)) used in connection with their businesses, and there have
                        been no breaches, violations, outages or unauthorized uses of or accesses to same, nor any incidents under internal review or investigations relating to the same, except as would not, individually or in the aggregate, reasonably be
                        expected to result in a material adverse effect on the Company and its subsidiaries taken as a whole. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules
                        and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT
                        Systems and Personal Data from unauthorized use, access, misappropriation or modification, except for such noncompliance as would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect
                        on the Company and its subsidiaries taken as a whole.</div>
                      <div> <br>
                      </div>
                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                      <div>
                        <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(mm)&#160; The Company has filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or has requested extensions thereof
                          (except, in each case, where the failure to file would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole) and has paid all taxes
                          required to be paid thereon (except for cases in which the failure to file or pay would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or, except as currently
                          being contested in good faith and for which reserves required by U.S. GAAP have been recorded in the financial statements of the Company), and there is no tax deficiency which if determined adversely to the Company would
                          reasonably be expected to have (nor does the Company have any notice or knowledge of any tax deficiency which would reasonably be expected to be determined adversely to the Company and which would reasonably be expected to have) a
                          material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
                        <div> <br>
                        </div>
                        <div>
                          <div style="padding: 0px 0px 0px 36pt; text-indent: 36pt;">(nn)&#160; Except as disclosed in the Time of Sale Prospectus or the Registration Statement, the Company and each of its subsidiaries are presently in compliance in all
                            material respects with all applicable privacy and data protection laws, judgments, orders, and other contractual or legal obligations binding on the Company or its subsidiaries; statutes, rules and regulations of any court or
                            arbitrator or other governmental or regulatory authority, in each case, relating to the privacy and security of the information technology systems and personal data used in connection with the operation of the Company&#8217;s and its
                            subsidiaries&#8217; businesses as currently conducted. The Company and each of its subsidiaries have, in accordance with industry standard practices for companies comparable in size to the Company, taken steps designed to protect the
                            information technology systems and personal data of the Company used in connection with the operation of the Company&#8217;s and its subsidiaries&#8217; businesses. Except as disclosed in the Time of Sale Prospectus or the Registration
                            Statement and to the knowledge of the Company, there has been no material security breach, compromise, misuse, misappropriation, or unauthorized use, access, disablement, or modification of or relating to any such information
                            technology system or personal data, and the Company and its subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any material security breach,
                            compromise, misuse, misappropriation, or unauthorized use, access, disablement, or modification of or relating to any such information technology system or personal data.</div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div> <br>
    <div style="text-align: justify; text-indent: 36pt;">
      <div><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;&#160; </font><br>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Subject to the terms and conditions herein set forth, (a) the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and
      not jointly, to purchase from the Company, at a purchase price per share of $49.1825, the number of Firm Securities set forth opposite the name of such Underwriter in Schedule I hereto and (b) in the event and to the extent that the Underwriters
      shall exercise the election to purchase Optional Securities as provided below, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the
      purchase price per share set forth in clause (a) of this Section 2 (provided that the purchase price per Optional Security shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm
      Securities but not payable on the Optional Securities), that portion of the number of Optional Securities as to which such election shall have been exercised (to be adjusted by you so as to eliminate fractional shares) determined by multiplying such
      number of Optional Securities by a fraction, the numerator of which is the maximum number of Optional Securities which such Underwriter is entitled to purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the
      denominator of which is the maximum number of Optional Securities that all of the Underwriters are entitled to purchase hereunder.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company hereby grants to the Underwriters the right to purchase at their election up to 1,893,203 Optional Securities, at the purchase price per share set forth in the
      paragraph above, provided that the purchase price per Optional Security shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Securities but not payable on the Optional
      Securities.&#160; Any such election to purchase Optional Securities may be exercised only by written notice from you to the Company, given within a period of 30 calendar days after the date of this Agreement, setting forth the aggregate number of Optional
      Securities to be purchased and the date on which such Optional Securities are to be delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in Section 4(a) hereof) or, unless you and the Company otherwise
      agree in writing, earlier than one or later than ten business days after the date of such notice.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Upon the authorization by you of the release of the Securities, the several Underwriters propose to offer the Securities for sale upon the terms and conditions set forth in the
      Pricing Prospectus, as supplemented by the information listed on Schedule II(c) hereto (the &#8220;Pricing Disclosure Package&#8221;) and the Prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">(a)&#160; The Securities to be purchased by each Underwriter hereunder, in book-entry form, and in such authorized denominations and registered in such names as the Representatives
      may request upon at least twenty-four hours&#8217; prior notice to the Company shall be delivered by or on behalf of the Company to the Representatives, through the facilities of the Depository Trust Company (&#8220;DTC&#8221;), for the account of such Underwriter,
      against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal (same-day) funds to the account specified by the Company to the Representatives at least twenty-four hours in advance.&#160; The time and date
      of such delivery and payment shall be, with respect to the Firm Securities, 9:30 a.m., New York City time, on May 31, 2024 or such other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional
      Securities, 9:30 a.m., New York time, on the date specified by the Representatives in the written notice given by the Representatives of the Underwriters&#8217; election to purchase such Optional Securities, or such other time and date as the
      Representatives and the Company may agree upon in writing.&#160; Such time and date for delivery of the Firm Securities is herein called the &#8220;First Time of Delivery&#8221;, such time and date for delivery of the Optional Securities, if not the First Time of
      Delivery, is herein called the &#8220;Second Time of Delivery&#8221;, and each such time and date for delivery is herein called a &#8220;Time of Delivery&#8221;.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The documents to be delivered at each Time of Delivery by or on behalf of the parties hereto pursuant to Section 8 hereof, including the cross-receipt for the Securities and
      any additional documents requested by the Underwriters pursuant to Section 8(m) hereof, will be delivered at the offices of Ropes &amp; Gray LLP 800 Boylston Street, Boston, Massachusetts, 02199-3600 (the &#8220;Closing Location&#8221;), and the Securities will
      be delivered in book-entry form through the facilities of the DTC, all at such Time of Delivery.&#160; For the purposes of this Section 4, &#8220;New York Business Day&#8221; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which
      banking institutions in New York City are generally authorized or obligated by law or executive order to close.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company<font style="font-weight: bold;">&#160;</font>agrees with each of the Underwriters:</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act prior to the earlier of (i) the First Time of Delivery and
      (ii) the Commission's close of business on the second business day following the execution and delivery of this Agreement; to make no further amendment or any supplement to the Registration Statement, the Basic Prospectus or the Prospectus prior to
      the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required in connection with
      the offering or sale of the Securities, to advise you, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has
      been filed and to furnish you with copies thereof; to file promptly all other material required to be filed by the Company with the Commission pursuant to Rule 433(d) under the Act; to file promptly all reports and any definitive proxy or information
      statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the
      notice referred to in Rule 173(a) under the Act) is required in connection with the offering or sale of the Securities; for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required
      in connection with the offering or sale of the Securities, to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or
      other prospectus in respect of the Securities, of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act, of the suspension of the
      qualification of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or
      the Prospectus or for additional information; and, in the event of the issuance of any such stop order or of any such order preventing or suspending the use of any Preliminary Prospectus or other prospectus or suspending any such qualification, to
      promptly use its reasonable best efforts to obtain the withdrawal of such order; and in the event of any such issuance of a notice of objection, promptly to take such steps including, without limitation, amending the Registration Statement or filing
      a new registration statement, at its own expense, as may be necessary to permit offers and sales of the Securities by the Underwriters (references herein to the Registration Statement shall include any such amendment or new registration statement);</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">If required by Rule 430B(h) under the Act, to prepare a form of prospectus in a form approved by you and to file such form of prospectus pursuant to Rule 424(b) under the Act
      not later than may be required by Rule 424(b) under the Act; and to make no further amendment or supplement to such form of prospectus which shall be disapproved by you promptly after reasonable notice thereof;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">[Reserved]</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Promptly from time to time to take such action as you may reasonably request to qualify the Securities<font style="font-weight: bold;">&#160;</font>for offering and sale under the
      securities laws of such jurisdictions as you may reasonably request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the
      Securities, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement and from time to time, to furnish the Underwriters with written
      and electronic copies of the Prospectus in New York City in such quantities as you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to
      the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Securities and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented
      would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu thereof, the
      notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated
      by reference in the Prospectus in order to comply with the Act or the Exchange Act, to notify you and upon your request to file such document and to prepare and furnish without charge to each Underwriter and to any dealer in securities as many
      written and electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required
      to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of the Securities at any time nine months or more after the time of issue of the Prospectus, upon your request but at
      the expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the Act;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">To make generally available to its securityholders as soon as practicable, but in any event not later than sixteen months after the effective date of the Registration Statement
      (as defined in Rule 158(c) under the Act), an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section 11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the
      option of the Company, Rule 158);</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">During the period beginning from the date hereof and continuing to and including the date 60 calendar days after the date of the Prospectus, not to (i) offer, sell, contract to
      sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a registration statement under the Act relating to, any securities of the Company that are
      substantially similar to the Securities, including but not limited to any options or warrants to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such
      substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of
      ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise (other than the Securities to be sold
      hereunder or pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date of this Agreement), without your prior written consent.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The restrictions contained in the preceding paragraph shall not apply to (i) the Securities to be sold hereunder, (ii) the issuance and sale of Stock pursuant to that certain Sales Agreement dated as
      of February 22, 2024, between the Company and Leerink Partners LLC, provided that no sales shall be made under the Sales Agreement until 30 calendar days after the date hereof, (iii)(A) the issuance by the Company of Stock upon the exercise of
      outstanding stock options or other stock-based awards or vesting of outstanding restricted stock units or other stock-based awards or issuances of shares of Stock under the 2000 Plan, the 2013 Plan, the 2015 Plan, the 2017 Plan or the 2019 Plan or
      pursuant to inducement grants to new employees or upon the exercise of currently outstanding options granted outside of such plans, (B) the grant by the Company of stock options, restricted stock units or other stock-based awards under the 2019 Plan
      or pursuant to inducement grants to new employees or (C) the conversion of a security outstanding on the date hereof described in the Registration Statement or of which the Underwriters have been advised in writing, (iv) issuances of Stock or other
      securities in connection with a transaction that includes a commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets
      or at least a controlling portion of the equity of another entity provided that (x) the aggregate number of shares of securities issued pursuant to this clause (iv) shall not exceed 10% of the total number of outstanding shares of Stock immediately
      following the issuance and sale of the Securities pursuant hereto and (y) the holder of such shares or securities shall sign a lock-up agreement in the form attached hereto as Annex I if the issuance of Stock or other securities occurs during the
      60-day restricted period, (v) the issuance of up to 184,433 shares of Stock to the legacy equityholders of Motus Biosciences, Inc. pursuant to the terms of the Business Combination Agreement, dated August 4, 2021, by and among the Company, Motus
      Biosciences, Inc., Boomerang M, Inc. and Shareholder Representative Services LLC or (vi) the issuance of up to 5,746,140 shares of Stock in connection with the conversion, redemption or repurchase of some or all of the Company&#8217;s 1.75% convertible
      senior notes due 2025;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">To pay the required Commission filing fees relating to the Securities within the time required by Rule 456(b)(1) under the Act without regard to the proviso therein and
      otherwise in accordance with Rules 456(b) and 457(r) under the Act;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">To use the net proceeds received by it from the sale of the Securities pursuant to this Agreement in the manner specified in the Pricing Prospectus under the caption &#8220;Use of
      Proceeds&#8221;;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">To use its reasonable best efforts to list the Securities on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;); and</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Upon reasonable request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company&#8217;s name and corporate logo for use on
      the website, if any, operated by such Underwriter for the purpose of facilitating the on-line offering of the Securities in accordance with this Agreement (the &#8220;License&#8221;); <font style="font-style: italic;">provided, however</font>, that the License
      shall be used solely for the purpose described above, is granted without any fee and may not be assigned, sublicensed or transferred and shall terminate upon the sale of all of the Securities allocated to such Underwriter on Schedule I.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">(a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer relating to the Securities that would
      constitute a &#8220;free writing prospectus&#8221; as defined in Rule 405 under the Act; each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not made and will not make any offer relating to the
      Securities that would constitute a free writing prospectus required to be filed with the Commission; any such free writing prospectus the use of which has been consented to by the Company and the Representatives is listed on Schedule II(a) hereto;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the
      Commission or retention where required and legending;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus or Written Testing-the-Waters Communication, for so long as the delivery of a
      prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required in connection with the offering or sale of the Securities, any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or
      Written Testing-the-Waters Communication would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary
      in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without
      charge to each Underwriter an Issuer Free Writing Prospectus, Written Testing-the-Waters Communication or other document which will correct such conflict, statement or omission; provided, however, that this representation and warranty shall not apply
      to any statements or omissions in an Issuer Free Writing Prospectus made in reliance upon and in conformity with the &#8220;Underwriter Information&#8221;;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company represents and agrees that (i) it has not engaged in, or authorized any other person to engage in, any Testing-the-Waters Communications, other than
      Testing-the-Waters Communications with the prior consent of the Representatives with entities that the Company reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors
      as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act; and (ii) it has not distributed, or authorized any other person to distribute, any Written Testing-the-Waters Communication, other than those distributed with the prior
      consent of the Representatives that are listed on Schedule II(d) hereto; and the Company reconfirms that the Underwriters have been authorized to act on its behalf in engaging in Testing-the-Waters Communications; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#160;(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Each Underwriter represents and agrees that any Testing-the-Waters Communications undertaken by it were with entities that such Underwriter reasonably believes are qualified
      institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the following: (i) the fees, disbursements and expenses of the
      Company's counsel and accountants in connection with the registration of the Securities under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the Registration Statement, the Basic Prospectus,
      any Preliminary Prospectus, any Written Testing-the-Waters Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers;
      (ii) the cost of printing or producing this Agreement, the Blue Sky memorandum, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Securities; (iii) all
      expenses in connection with the qualification of the Securities<font style="font-weight: bold;">&#160;</font>for offering and sale under state securities laws as provided in Section 5(c) hereof, including filing fees and the reasonable fees and
      disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey; (iv) all fees and expenses in connection with listing the Securities on Nasdaq; (v) the filing fees incident to, and the
      fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA. of the terms of the sale of the Securities; (vi) the cost of preparing the Securities; (vii) the cost and charges of any transfer agent or
      registrar; (viii) the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Securities, including, without limitation, expenses associated with the
      production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior written approval of the Company, travel and lodging expenses of the representatives and officers
      of the Company and any such consultants, and the cost of any aircraft chartered in connection with any road show (provided that the prior written approval of the Company is obtained prior to the chartering of any such aircraft), and (ix) all other
      costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that except as provided in this Section, and Sections 9 and 12 hereof,
      the Underwriters will pay all of their own costs and expenses, including the fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Securities by them, travel and lodging expenses of their representatives in
      connection with any road show and any advertising expenses connected with any offers they may make, it being further understood, however, that the fees and disbursements of counsel for the Underwriters to be paid by the Company pursuant to clauses
      (iii) and (v) above shall not exceed $10,000 in the aggregate.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The obligations of the Underwriters hereunder, as to the Securities to be delivered at each Time of Delivery, shall be subject, in their discretion, to the condition that all
      representations and warranties and other statements of the Company herein are, at and as of 6:00 p.m., New York City time, on the date of this Agreement (the &#8220;Applicable Time&#8221;) and such Time of Delivery, true and correct, the condition that the
      Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions:</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the Applicable Time period prescribed for such filing by the rules and
      regulations under the Act and in accordance with Section 5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission within the Applicable Time period prescribed for
      such filings by Rule 433; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose or pursuant to Section 8A of the Act shall have been initiated or
      threatened by the Commission and no notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act shall have been received; no stop order suspending or
      preventing the use of the Preliminary Prospectus, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission related to the
      offering or sale of the Securities shall have been complied with to your reasonable satisfaction;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Ropes &amp; Gray LLP, counsel for the Underwriters, shall have furnished to you their written 10b5-1 letter dated such Time of Delivery, in the form previously agreed;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Covington &amp; Burling LLP, special counsel for the Company, shall have furnished to you their written opinion, dated such Time of Delivery, in the form previously agreed;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Hunton Andrew Kurth LLP, Virginia counsel for the Company, shall have furnished to you their written opinion, dated such Time of Delivery, in the form previously agreed;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Cooley LLP, intellectual property counsel to the Company, shall have furnished to you their written opinion, dated such Time of Delivery, in the form previously agreed;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">On the date of the Prospectus upon the execution of this Agreement, at 9:30 a.m., New York City time, on the effective date of any post effective amendment to the Registration
      Statement filed subsequent to the date of this Agreement and also at each Time of Delivery, Ernst &amp; Young LLP, independent public accountants,<font style="font-weight: bold;">&#160;</font>shall have furnished to you a letter or letters, dated the
      respective dates of delivery thereof, in the form previously agreed;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">(i)&#160; Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included or incorporated by reference in the
      Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth
      or contemplated in the Pricing Prospectus, and (ii) since the respective dates as of which information is given in the Pricing Prospectus there shall not have been any change in the capital stock or long term debt of the Company or any of its
      subsidiaries or any change or effect, or any development involving a prospective change or effect, in or affecting (x) the business, properties, general affairs, management, financial position, stockholders' equity or results of operations of the
      Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (y) the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Securities, or to
      consummate the transactions contemplated in the Pricing Prospectus and the Prospectus, the effect of which, in any such case described in clause (i) or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to
      proceed with the public offering or the delivery of the Securities being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">On or after the Applicable Time (i) no downgrading shall have occurred in the rating accorded the Company's debt securities by any &#8220;nationally recognized statistical rating
      organization&#8221;, as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Act, and (ii) no such organization shall have publicly announced that it has under surveillance or review, with possible negative implications, its
      rating of any of the Company's debt securities;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">On or after the Applicable Time there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York
      Stock Exchange or the Nasdaq Global Select Market; (ii) a suspension or material limitation in trading in the Company&#8217;s securities on Nasdaq; (iii) a general moratorium on commercial banking activities declared by either Federal or New York State
      authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a
      national emergency or war or (v) the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv) or (v) in your
      judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Securities being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company shall have complied with the provisions of Section 5(e) hereof with respect to the furnishing of prospectuses on the New York Business Day next succeeding the date
      of this Agreement;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Securities shall have been duly listed on Nasdaq;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from each executive officer and director of the Company listed on Schedule IV
      hereto, in the form attached hereto as Annex I; and</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of the Company in the form previously agreed as to the
      accuracy of the representations and warranties of the Company herein at and as of such time, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to such time, as to the matters set forth in subsections
      (a) and (g) of this Section and as to such other matters as you may reasonably request.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">(a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become
      subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) are caused by an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the
      Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any &#8220;road show&#8221; as defined in Rule 433(h) under the Act (a &#8220;road show&#8221;), any &#8220;issuer
      information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Act or any Testing-the-Waters Communication, or are caused by the omission or alleged omission to state therein a material fact required to be stated therein or necessary to
      make the statements therein (solely with respect to the Prospectus, in light of the circumstances under which they were made) not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter
      in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of
      or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or
      supplement thereto, or any Issuer Free Writing Prospectus, or any Testing-the-Waters Communication, in reliance upon and in conformity with the Underwriter Information (as defined below).</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Each Underwriter will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Act or
      otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Basic
      Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any road show, or any Testing-the-Waters Communication, or arise out of or are based
      upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged
      untrue statement or omission or alleged omission was made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus or any such amendment or supplement thereto, or any Issuer Free
      Writing Prospectus, or any roadshow or any Testing-the-Waters Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in
      connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, &#8220;Underwriter Information&#8221; shall mean the written information
      furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the
      Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the fifth paragraph under the caption &#8220;Underwriting&#8221;, and the information contained in the ninth, tenth and eleventh paragraphs under the caption
      &#8220;Underwriting.&#8221;</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in
      respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; provided that the failure to notify the indemnifying party shall not relieve it from any
      liability that it may have under the preceding paragraphs of this Section 9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure
      to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding paragraphs of this Section 9.&#160; In case any such action shall be brought against any indemnified party
      and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the
      defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnified party), and, after notice from the indemnifying party to such indemnified
      party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by
      such indemnified party, in connection with the defense thereof other than reasonable costs of investigation.&#160; No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the
      entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or
      claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault,
      culpability or a failure to act, by or on behalf of any indemnified party.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">If the indemnification provided for in this Section 9 is unavailable to or insufficient to hold harmless an indemnified party under subsection (a) or (b) above in respect of
      any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or
      liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Securities.&#160; If, however, the
      allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not
      only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in
      respect thereof), as well as any other relevant equitable considerations.&#160; The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the
      offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus.&#160; The relative fault shall
      be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the
      Underwriters on the other and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.&#160; The Company and the Underwriters agree that it would not be just and equitable if
      contribution pursuant to this subsection (d) were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable
      considerations referred to above in this subsection (d).&#160; The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be
      deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.&#160; Notwithstanding the provisions of this subsection (d), no Underwriter shall be
      required to contribute any amount in excess of the amount by which the total price at which the Securities underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has
      otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution
      from any person who was not guilty of such fraudulent misrepresentation.&#160; The Underwriters' obligations in this subsection (d) to contribute are several in proportion to their respective underwriting obligations and not joint.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The obligations of the Company under this Section 9 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same terms and
      conditions, to each employee, officer and director of each Underwriter, each person, if any, who controls any Underwriter within the meaning of the Act and each broker-dealer or other affiliate of any Underwriter; and the obligations of the
      Underwriters under this Section 9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company<font style="font-weight: bold;">&#160;</font>and to each person, if any, who controls the Company within the meaning of the Act.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">(a)&#160; If any Underwriter shall default in its obligation to purchase the Securities which it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion
      arrange for you or another party or other parties to purchase such Securities on the terms contained herein.&#160; If within thirty-six hours after such default by any Underwriter you do not arrange for the purchase of such Securities, then the Company
      shall be entitled to a further period of thirty-six hours within which to procure another party or other parties satisfactory to you to purchase such Securities on such terms.&#160; In the event that, within the respective prescribed periods, you notify
      the Company that you have so arranged for the purchase of such Securities, or the Company notifies you that it has so arranged for the purchase of such Securities, you or the Company shall have the right to postpone such Time of Delivery for a period
      of not more than seven calendar days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any amendments
      or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term &#8220;Underwriter&#8221; as used in this Agreement shall include any person substituted under this Section with like effect as if such
      person had originally been a party to this Agreement with respect to such Securities.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a)
      above, the aggregate number of such Securities which remains unpurchased does not exceed one tenth of the aggregate number of all the Securities to be purchased at such Time of Delivery, then the Company shall have the right to require each
      non-defaulting Underwriter to purchase the number of shares which such Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require each non-defaulting Underwriter to purchase its pro rata share (based on the number
      of Securities which such Underwriter agreed to purchase hereunder) of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from
      liability for its default.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a)
      above, the aggregate number of such Securities which remains unpurchased exceeds one tenth of the aggregate number of all the Securities to be purchased at such Time of Delivery, or if the Company shall not exercise the right described in subsection
      (b) above to require non-defaulting Underwriters to purchase Securities of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the
      Company to sell the Optional Securities) shall thereupon terminate, without liability on the part of any non-defaulting Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section 7
      hereof and the indemnity and contribution agreements in Section 9 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The respective indemnities, rights of contribution, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in
      this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or
      any director, officer, employee, affiliate or controlling person of any Underwriter, or the Company, or any officer or director or controlling person of the Company, and shall survive delivery of and payment for the Securities.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">If this Agreement shall be terminated pursuant to Section 10 hereof, the Company shall not then be under any liability to any Underwriter except as provided in Sections 7 and 9
      hereof; but, if for any other reason, any the Securities are not delivered by or on behalf of the Company as provided herein (unless such failure to comply or inability to perform is due primarily to any default of any Underwriter), the Company will
      reimburse the Underwriters through you for all out of pocket expenses approved in writing by you, including reasonable and documented fees and disbursements of counsel, reasonably incurred by the Underwriters in making preparations for the purchase,
      sale and delivery of the Securities not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9 hereof.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">In all dealings hereunder, you shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to act and rely upon any statement, request, notice or
      agreement on behalf of any Underwriter made or given by you jointly or by Goldman Sachs &amp; Co. LLC and Leerink Partners LLC on behalf of you as the representatives.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to you as the
      representatives in care of Goldman Sachs &amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department and Leerink Partners LLC, 1301 Avenue of the Americas, 12<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York, New York 10019, Attention: Stuart R. Nayman; and if to the Company shall be delivered or sent by mail to the address of the Company set forth in the Registration Statement, Attention: Secretary;
      provided, however, that any notice to an Underwriter pursuant to Section 9(c) hereof shall be delivered or sent by mail, telex or facsimile transmission to such Underwriter at its address set forth in its &#8220;Underwriters' Questionnaire&#8221;, or telex
      constituting such Questionnaire, which address will be supplied to the Company by you upon request.&#160; Any such statements, requests, notices or agreements shall take effect upon receipt thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the underwriters are required to obtain, verify and record information
      that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow&#160; the underwriters to properly identify their respective
      clients.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in Sections 9 and 11 hereof, the officers
      and directors of the Company and each person who controls the Company or any Underwriter, or any director, officer, employee, or affiliate of any Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other
      person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Securities from any Underwriter shall be deemed a successor or assign by reason merely of such purchase.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Time shall be of the essence of this Agreement.&#160; As used herein, the term &#8220;business day&#8221; shall mean any day when the Commission's office in Washington, D.C. is open for
      business.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company acknowledges and agrees that (i) the purchase and sale of the Securities pursuant to this Agreement is an arm's-length commercial transaction between the Company,
      on the one hand, and the several Underwriters, on the other, (ii) in connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii) no
      Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the
      Company on other matters) or any other obligation to the Company except the obligations expressly set forth in this Agreement, (iv) the Company has consulted its own legal and financial advisors to the extent it deemed appropriate, and (v) none of
      the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person.&#160; The Company
      agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the
      subject matter hereof.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">This Agreement and any transaction contemplated by this Agreement shall be governed by and construed in accordance with the laws of the State
        of New York without regard to principles of conflict of laws that would results in the application of any other law than the laws of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any
        transaction contemplated by this Agreement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of
        New York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts.</font></div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
      proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such respective
      counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
      the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
      purposes.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Notwithstanding anything herein to the contrary, the Company is authorized to disclose to any persons the U.S. federal and state income tax treatment and tax structure of the
      potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company relating to that treatment and structure, without the Underwriters&#8217; imposing any limitation of any kind. However, any
      information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, &#8220;tax structure&#8221; is
      limited to any facts that may be relevant to that treatment.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">Recognition of the U.S. Special Resolution Regimes.</div>
    <div style="text-indent: 36pt;"> <br>
    </div>
    <div style="text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this
      Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
      governed by the laws of the United States or a state of the United States.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">(b) </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,
      Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed
      by the laws of the United States or a state of the United States.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(c) </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">As used in this section:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;Covered Entity&#8221; means any of the following:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer
      Protection Act and the regulations promulgated thereunder.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">If the foregoing is in accordance with your understanding, please sign and return to us counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this letter
      and such acceptance hereof shall constitute a binding agreement between each of the Underwriters and the Company.&#160; It is understood that your acceptance of this letter on behalf of each of the Underwriters is pursuant to the authority set forth in a
      form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on your part as to the authority of the signers thereof.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">
      <table cellspacing="0" cellpadding="0" border="0" id="zdf02887ab20d4e1f8f55da0918bb8d0a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;"><br>
            </td>
            <td colspan="2" rowspan="1" style="width: 5%;">Very truly yours,<br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; font-weight: bold;">Insmed Incorporated</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 45%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="border-bottom: 2px solid #000000; width: 45%; text-indent: 0px;">/s/ Sara Bonstein<br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%; text-indent: 0px;">Name: Sara Bonstein<br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%; text-indent: 0px;">Title: Chief Financial Officer<br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%;">&#160;</td>
          </tr>

      </table>
    </div>
    <div>Accepted as of the date hereof:</div>
    <div>&#160;</div>
    <div style="font-weight: bold;">Goldman Sachs &amp; Co. LLC</div>
    <div style="font-weight: bold;"> <br>
    </div>
    <div style="font-weight: bold;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 5%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 45%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Lyla Bibi Maduri<br>
            </td>
            <td style="width: 50%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%;">Name: Lyla Bibi Maduri</td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%;">Title: Managing Director<br>
            </td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;"><br>
            </td>
            <td rowspan="1" style="width: 45%;">&#160;</td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="font-weight: bold;">Leerink Partners LLC</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 5%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 45%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Sean Pitt<br>
            </td>
            <td style="width: 50%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%;">Name: Sean Pitt<br>
            </td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 45%;">Title: Senior Managing Director<br>
            </td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;"><br>
            </td>
            <td rowspan="1" style="width: 45%;">&#160;</td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%-%-%-->
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z355eec9281a644eb95bbe44872d43047">

        <tr>
          <td colspan="3" style="width: 100%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">SCHEDULE I</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top;">&#160;</td>
          <td rowspan="5" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 20.32%;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">Total Number of</div>
            <div style="text-align: center; font-weight: bold;">Firm Securities</div>
            <div style="text-align: center; font-weight: bold;">to be Purchased</div>
          </td>
          <td rowspan="5" style="width: 27.01%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">Number of Optional</div>
            <div style="text-align: center; font-weight: bold;">Securities to be</div>
            <div style="text-align: center; font-weight: bold;">Purchased if</div>
            <div style="text-align: center; font-weight: bold;">Maximum Option</div>
            <div>
              <div style="text-align: center; font-weight: bold;">Exercised</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 52.67%;">
            <div style="text-align: center; font-weight: bold;">Underwriter</div>
          </td>
        </tr>
        <tr>
          <td style="background-color: #CCEEFF; vertical-align: top; width: 52.67%;">
            <div>Goldman Sachs &amp; Co. LLC</div>
          </td>
          <td style="width: 20.32%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">4,165,048</div>
          </td>
          <td style="width: 27.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">624,757</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top;">
            <div>Leerink Partners LLC</div>
          </td>
          <td style="width: 20.32%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">3,407,767</div>
          </td>
          <td style="width: 27.01%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">511,165</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>J.P. Morgan Securities LLC</div>
          </td>
          <td style="width: 20.32%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">2,524,272</div>
          </td>
          <td style="width: 27.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">378,641</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top;">
            <div>Morgan Stanley &amp; Co. LLC</div>
          </td>
          <td style="width: 20.32%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">1,262,136</div>
          </td>
          <td style="width: 27.01%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">189,320</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Cantor Fitzgerald &amp; Co.</div>
          </td>
          <td style="width: 20.32%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">631,068</div>
          </td>
          <td style="width: 27.01%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">94,660</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top; padding-bottom: 2px;">
            <div>Stifel, Nicolaus &amp; Company, Incorporated</div>
          </td>
          <td style="width: 20.32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">631,068</div>
          </td>
          <td style="width: 27.01%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">94,660</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.67%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="margin: 0px 0px 0px 9pt;">Total</div>
          </td>
          <td style="width: 20.32%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); text-align: center;">12,621,359</td>
          <td rowspan="1" style="width: 20.5%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); text-align: center;">1,893,203</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE II</div>
    <div>&#160;</div>
    <div>(a) Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package:</div>
    <div style="margin-left: 36pt; font-family: 'Times New Roman',Times,serif;">None</div>
    <div> <br>
    </div>
    <div>(b) Additional Documents Incorporated by Reference:</div>
    <div style="text-indent: 36pt;">None</div>
    <div><br>
    </div>
    <div>(c) Information other than the Pricing Prospectus that comprise the Pricing Disclosure Package:</div>
    <div style="text-indent: 36pt;">The public offering price per share for the Securities is $51.50.</div>
    <div style="text-indent: 36pt;">The number of Securities purchased by the Underwriters is 12,621,359.</div>
    <div><br>
    </div>
    <div>(d) Written Testing-the-Waters Communications</div>
    <div style="text-indent: 36pt;">None</div>
    <div style="text-align: center; text-indent: 36pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="font-weight: bold; text-align: center;">SCHEDULE III</div>
    <div>&#160;</div>
    <div style="font-weight: bold; text-align: center;">List of Subsidiaries</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf8e8fabbee914f4698a13a5bfa2311a1">

        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="font-weight: bold; text-align: center;">Name</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold; text-align: center;">Jurisdiction of Incorporation</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Adrestia Therapeutics Inc.</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Delaware</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Celtrix Pharmaceuticals, Inc.</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Delaware</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Gene Therapy LLC</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Delaware</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Limited</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">England and Wales</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Holdings Limited </div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Ireland</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Innovation UK Limited</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">England and Wales</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Ireland Limited</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Ireland</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Netherlands Holdings B.V.</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">The Netherlands</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Netherlands B.V.</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">The Netherlands</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Germany GmbH</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Germany</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed France SAS</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">France</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Godo Kaisha</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Japan</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Switzerland GmbH</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Switzerland</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Insmed Italy S.R.L.</div>
          </td>
          <td style="width: 50%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Italy</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-weight: bold; text-align: center;">SCHEDULE IV</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z40ab2e68d11944c5a83cb0c3d1b8d635">

        <tr>
          <td style="width: 39.64%; vertical-align: top; border-bottom: #000000 4px double;">
            <div style="color: #000000; font-weight: bold;">Name of Stockholder</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-bottom: #000000 4px double;">
            <div style="color: #000000; font-weight: bold;">Title</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">William H. Lewis</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Sara Bonstein</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Roger Adsett</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief Operating Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Martina Flammer, M.D.</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief Medical Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">S. Nicole Schaeffer</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief People Strategy Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Michael A. Smith</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief Legal Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Drayton Wise</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Chief Commercial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Alfred A. Altomari</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Elizabeth McKee Anderson</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">David R. Brennan</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Clarissa Desjardins</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Leo Lee</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">David W.J. McGirr</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Carol A. Schafer</div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double; border-bottom: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.64%; vertical-align: top; border-top: #000000 4px double;">
            <div style="text-indent: -17.1pt; margin-left: 17.1pt; color: #000000;">Melvin Sharoky, M.D. </div>
          </td>
          <td style="width: 60.36%; vertical-align: top; border-top: #000000 4px double;">
            <div style="color: #000000;">Director</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; font-weight: bold;">ANNEX I</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">FORM OF LOCK-UP AGREEMENT</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">INSMED INCORPORATED</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Lock-Up Agreement</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">______, 2024</div>
    <div style="text-align: justify;">Goldman Sachs &amp; Co. LLC</div>
    <div style="text-align: justify;">Leerink Partners LLC</div>
    <div><br>
    </div>
    <div style="text-align: justify;">As Representatives of the several Underwriters</div>
    <div style="text-align: justify;">named in Schedule I to the Underwriting Agreement</div>
    <div><br>
    </div>
    <div style="text-align: justify;">c/o Goldman Sachs &amp; Co. LLC</div>
    <div style="text-align: justify;">200 West Street</div>
    <div style="text-align: justify;">New York, New York 10282-2198</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div>c/o Leerink Partners LLC <br>
    </div>
    <div>53 State Street, 40<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
    <div>Boston, Massachusetts 02109</div>
    <div> <br>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb4a0c215be04e10843108471e9ad4c9">

        <tr>
          <td style="width: 46.8pt;"><br>
          </td>
          <td style="width: 25.2pt; vertical-align: top;">Re:</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Insmed Incorporated - Lock-Up Agreement</u></div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">Ladies and Gentlemen:</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned understands that you, as representatives (the &#8220;Representatives&#8221;), propose to enter into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) on behalf of the several underwriters
      named in Schedule I to such agreement (collectively, the &#8220;Underwriters&#8221;), with Insmed Incorporated, a Virginia corporation (the &#8220;Company&#8221;), providing for a public offering (the &#8220;Public Offering&#8221;) of shares (the &#8220;Shares&#8221;) of the common stock, par
      value $0.01 per share, of the Company (the &#8220;Common Stock&#8221;) pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-272088) (the &#8220;Registration Statement&#8221;), which was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) and
      became automatically effective on May 19, 2023.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the
      undersigned agrees that, during the period beginning from the date of this Lock-Up Agreement and continuing to and including the date 60 days after the date of the final prospectus relating to the Public Offering (the &#8220;Prospectus&#8221;) (such period, the
      &#8220;Lock-Up Period&#8221;), the undersigned shall not, and shall not cause or direct any of its affiliates to, (i) offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or
      otherwise transfer or dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock (such
      shares of Common Stock, options, rights, warrants or other securities, collectively, &#8220;Lock-Up Securities&#8221;), including without limitation any such Lock-Up Securities now owned or hereafter acquired by the undersigned, (ii) engage in any hedging or
      other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however
      described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic
      consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities,
      in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a &#8220;Transfer&#8221;), (iii) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities or (iv) otherwise
      publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described in clause (i), (ii) or (iii) above. Other than (i) pursuant to a written plan meeting the requirements of Rule 10b5-1 under the
      Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) (a &#8220;10b5-1 trading plan&#8221;) existing on the date hereof or (ii) any &#8220;sell to cover arrangement&#8221; for the payment of taxes, including estimated taxes, and remittance payments due as a
      result of the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock that are scheduled to expire or automatically vest during the Lock-Up Period, in all such cases pursuant to
      equity awards granted under a stock incentive plan or other equity award plan, or pursuant to the terms of convertible securities, each as described in the Registration Statement, the preliminary prospectus relating to the Shares included in the
      Registration Statement immediately prior to the time the Underwriting Agreement is executed and the Prospectus, the undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become,
      currently a party to any agreement or arrangement that provides for, is designed to or reasonably could be expected to lead to or result in any Transfer during the Lock-Up Period.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Notwithstanding the foregoing, the undersigned may:</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08efe2a672ae41e2b6cf1f1151a67d3a">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>transfer the undersigned&#8217;s Lock-Up Securities (i) as one or more <font style="font-style: italic;">bona fide</font> gifts or by will, other testamentary document or intestate succession, (ii) as distributions to limited partners, members,
              stockholders, or wholly-owned subsidiaries of the undersigned, (iii) pursuant to any order or settlement agreement not involving any public sale of shares of Common Stock or other securities and approved by any court of competent
              jurisdiction, (iv) if the undersigned is a natural person, to any member of the undersigned&#8217;s immediate family (for purposes of this Lock-Up Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, current or former marriage,
              domestic partnership or adoption, not more remote than first cousin) or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned or, if the undersigned is a trust, to a trustor or
              beneficiary of the trust or the estate of a beneficiary of such trust, (v) to any corporation, partnership, limited liability company or similar entity of which all of the beneficial ownership interests are held by the undersigned or the
              immediate family of the undersigned; provided that in the case of any transfer or distribution pursuant to clauses (i)-(v), (a) each donee, distributee or transferee shall sign and deliver to the Representatives a lock-up agreement
              substantially in the form of this Lock-Up Agreement, (b) no public announcement or filing by any party (the undersigned, donor, donee, distributor, distributee, transferor or transferee) under the Exchange Act, including, without limitation,
              any Section 16(a) filing, shall be voluntarily made in connection with such transfer or distribution; provided that if any such filing, report or announcement shall be legally required during the Lock-Up Period, such filing, report or
              announcement shall clearly indicate in the footnotes thereto (x) the circumstances of such transfer or distribution and (y) in the case of a transfer or distribution pursuant to clause (iv), that the donee, devisee, transferee or distributee
              has agreed to be bound by a lock-up agreement substantially in the form of this Lock-Up Agreement, and (c) any such transfer or distribution shall not involve a disposition for value, (vi) in connection with the exercise of options or other
              stock-based awards to purchase Common Stock or vesting of restricted stock units or other stock-based awards outstanding as of the date hereof or granted under equity incentive plans or pursuant to inducement awards in effect as of the date
              hereof or described in the Registration Statement, the preliminary prospectus relating to the Shares included in the Registration Statement immediately prior to the time the Underwriting Agreement is executed and the Prospectus; provided that
              the underlying Common Stock continues to be subject to the terms of this Lock-Up Agreement, (vii) for the repurchase by the Company or forfeiture of securities to the Company in connection with termination of the undersigned&#8217;s employment with
              the Company, (viii) to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221;
              exercise) that are scheduled to expire or automatically vest during the Lock-Up Period, including any transfer to the Company for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of
              such restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to equity awards granted under a stock incentive plan or other equity award plan, or
              pursuant to the terms of convertible securities, each as described in the Registration Statement, the preliminary prospectus relating to the Shares included in the Registration Statement immediately prior to the time the Underwriting
              Agreement is executed and the Prospectus; provided that (a) any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of this Lock-Up Agreement and (b) any such settled or withheld shares are
              surrendered to the Company in the net exercise, and (ix) under a &#8220;sell to cover arrangement&#8221; for the payment of taxes, including estimated taxes, and remittance payments due as a result of the vesting, settlement or exercise of restricted
              stock units, options, warrants or other rights to purchase shares of Common Stock that are scheduled to expire or automatically vest during the Lock-Up Period, in all such cases pursuant to equity awards granted under a stock incentive plan
              or other equity award plan, or pursuant to the terms of convertible securities, each as described in the Registration Statement, the preliminary prospectus relating to the Shares included in the Registration Statement immediately prior to the
              time the Underwriting Agreement is executed and the Prospectus; provided that in each case (i) through (ix), that the undersigned shall provide you two days&#8217; advance notice of such transfers, distributions, exercises, repurchases,
              forfeitures, settlements or withholdings, as applicable;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb0c590ad83749cd874c8dc0c9b12b7c">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>(i) enter into a 10b5-1 trading plan relating to the transfer, sale or other disposition of the undersigned&#8217;s Lock-Up Securities, if then permitted by the Company, provided that none of the securities subject to such plan may be
              transferred, sold or otherwise disposed of until after the expiration of the Lock-Up Period and no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made
              regarding the establishment of such plan during the Lock-Up Period, and provided further that the undersigned shall provide you two days&#8217; advance notice of such plan establishment,&#160; and (ii) transfer shares of Common Stock pursuant to a
              10b5-1 trading plan entered into prior to the date of this Lock-Up Agreement, provided that to the extent a public announcement or filing under the Exchange Act is required for such transfer, such announcement or filing shall include a
              statement to the effect that the transfer was made pursuant to a 10b5-1 trading plan; and</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z70cb82f93b724f1a9ca7a294c27bc4eb">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>transfer the undersigned&#8217;s Lock-Up Securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company&#8217;s capital stock involving a Change of Control of the
              Company (for purposes hereof, &#8220;Change of Control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of
              affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)); provided that in
              the event that such tender offer, merger, consolidation or other similar transaction is not completed during the Lock-Up Period, the undersigned&#8217;s Lock-Up Securities shall remain subject to the provisions of this Lock-Up Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed or other Shares the
      undersigned may purchase in the Public Offering.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &#8220;group&#8221; (within the meaning of Section 13(d)(3) of the Exchange Act),
      other than a natural person, entity or &#8220;group&#8221; (as described above) that has executed a Lock-Up Agreement in substantially the same form as this Lock-Up Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests,
      or 50% or more of the voting power, in the undersigned.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned now has, and, except as contemplated by clauses (a) and (c) of the third paragraph of this Lock-Up Agreement or pursuant to any sales of Lock-Up Securities pursuant to a 10b5-1
      trading plan existing on the date hereof, for the duration of this Lock-Up Agreement will have, good and marketable title to the undersigned&#8217;s Lock-Up Securities, free and clear of all liens, encumbrances and claims whatsoever. The undersigned also
      agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s Lock-Up Securities except in compliance with the foregoing restrictions.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">This Lock-Up Agreement shall automatically terminate and the undersigned shall be released from all of his, her or its obligations hereunder upon the earlier of (i) the date on which the Registration
      Statement filed with the SEC with respect to the Public Offering is withdrawn, (ii) the date on which for any reason the Underwriting Agreement is terminated (other than the provisions thereof that survive termination) prior to payment for and
      delivery of the Shares to be sold thereunder (other than pursuant to the Underwriters&#8217; option thereunder to purchase additional Shares), (iii) the date on which the Company notifies the Representatives, in writing and prior to the execution of the
      Underwriting Agreement, that it does not intend to proceed with the Public Offering and (iv) June 30, 2024, in the event that the Underwriting Agreement has not been executed by such date.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned understands that the Company and the Underwriters are relying upon this Lock-Up Agreement in proceeding toward consummation of the Public Offering. The undersigned further understands
      that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns. The undersigned hereby represents and warrants that the undersigned has full power and authority to enter
      into this Lock-Up Agreement. This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflict of laws that would result in the application of any law other than
      the laws of the State of New York. This Lock-Up Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or
      other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%I-%%-->
    <div style="text-align: justify;">Very truly yours,</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">
      <table cellspacing="0" cellpadding="0" border="0" id="zf0908fa7324c444ead6ce271a00ec89c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td colspan="2" rowspan="1" style="width: 5%;">
              <div style="text-align: left; font-weight: bold;">IF AN INDIVIDUAL:</div>
            </td>
            <td style="width: 4%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="width: 5%;">
              <div style="text-align: left; font-weight: bold;">IF AN ENTITY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 43%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 43%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 43%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
            <td style="width: 4%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="width: 5%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;"><font style="font-style: italic;">(duly authorized signature)</font><br>
            </td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%;"><font style="font-style: italic;">(please print complete name of entity)</font><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;">&#160;</td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; padding-bottom: 2px;">Name:<br>
            </td>
            <td rowspan="1" style="width: 43%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 4%; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 5%; padding-bottom: 2px;">By:<br>
            </td>
            <td rowspan="1" style="width: 43%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;"><font style="font-style: italic;">(please print full name)</font><br>
            </td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;"><font style="font-style: italic;">(duly authorized signature)</font></td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;">&#160;</td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 4%; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 5%; padding-bottom: 2px;">Name:<br>
            </td>
            <td rowspan="1" style="width: 43%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;">&#160;</td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;"><font style="font-style: italic;">(please print full name)</font><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;">&#160;</td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 4%; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 5%; padding-bottom: 2px;">Title:<br>
            </td>
            <td rowspan="1" style="width: 43%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;">&#160;</td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 5%;">&#160;</td>
            <td rowspan="1" style="width: 43%; text-align: center;"><font style="font-style: italic;">(please print full title)</font></td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: center;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"><font style="font-weight: normal; font-style: normal;"> </font></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ny20029730x2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 5.1</font><br>
      <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5f748a72473b4b0c82217a4437ac7385">

        <tr>
          <td style="width: 69.48%; vertical-align: top;">
            <div style="text-align: left;"><img width="178" height="48" src="ny20029730x2_ex5-1img01.jpg"></div>
            <div>&#160;</div>
            <div>&#160;</div>
          </td>
          <td style="width: 30.52%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 69.48%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 30.52%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 69.48%; vertical-align: top;">&#160;</td>
          <td rowspan="2" style="width: 30.52%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 69.48%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 30, 2024</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed Incorporated</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">700 US Highway 202/206</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bridgewater, New Jersey 08807</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; text-align: center;">Insmed Incorporated</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Public Offering of 14,514,562 Shares of Common Stock</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed Incorporated:</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have acted as Virginia counsel to Insmed Incorporated, a Virginia corporation (the &#8220;Company&#8221;), in connection with the Company&#8217;s issuance
      and sale of 14,514,562 shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Shares&#8221;) pursuant to (i) the Registration Statement on Form S-3 (File No. 333-272088) filed by the Company with the Securities and Exchange Commission (the
      &#8220;Commission&#8221;) on May 19, 2023 (the &#8220;Registration Statement&#8221;) pursuant to the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and (ii) the prospectus, dated May 19, 2023, contained in the Registration Statement and the prospectus supplement
      thereto, dated May 29, 2024 (collectively, the &#8220;Prospectus&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This opinion letter is being furnished in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K.</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with this opinion letter, we have examined originals or copies, certified or otherwise identified to our satisfaction, of
      such documents and records of the Company, certificates of public officials and officers of the Company and such other documents, certificates and records as we have deemed necessary to render the opinions set forth herein, including, among other
      things, (i) the Company&#8217;s Articles of Incorporation, as amended through the date hereof, (ii) the Company&#8217;s Amended and Restated Bylaws, as amended through the date hereof, (iii) the Registration Statement, (iv) the Prospectus, (v) the Underwriting
      Agreement, dated as of May 29 2024 (the &#8220;Underwriting Agreement&#8221;), among the Company, Goldman Sachs &amp; Co. LLC, Leerink Partners LLC and the several underwriters (the &#8220;Underwriters&#8221;) named in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule I</u></font> to the Underwriting Agreement, for whom Goldman Sachs &amp; Co. LLC and Leerink Partners LLC are acting as representatives, (vi) resolutions of the Company&#8217;s Board of Directors and pricing committee
      thereof (the &#8220;Resolutions&#8221;) and (vii) a certificate issued by the State Corporation Commission of the Commonwealth of Virginia on the date hereof, to the effect that the Company is existing under the laws of the Commonwealth of Virginia and in good
      standing (the &#8220;Good Standing Certificate&#8221;).</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <div style="color: #7F7F7F; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: center; text-indent: 0px;">ATLANTA&#160;&#160; AUSTIN&#160;&#160; BANGKOK&#160;&#160; BEIJING&#160;&#160; BOSTON&#160;&#160; BRUSSELS&#160;&#160; CHARLOTTE&#160;&#160; DALLAS&#160;&#160; DUBAI&#160;&#160; HOUSTON</div>
      <div style="color: #7F7F7F; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: center; text-indent: 0px;">LONDON&#160;&#160; LOS ANGELES&#160;&#160; MIAMI&#160;&#160; NEW YORK&#160;&#160; RICHMOND&#160;&#160; SAN FRANCISCO&#160;&#160; TOKYO&#160;&#160; TYSONS&#160;&#160; WASHINGTON, DC</div>
      <div style="color: #7F7F7F; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: center; text-indent: 0px;">www.HuntonAK.com</div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 69.48%; vertical-align: top;">
              <div style="text-align: left;"><img width="178" height="48" src="ny20029730x2_ex5-1img01.jpg"></div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 69.48%; vertical-align: top;">Insmed Incorporated<br>
            </td>
          </tr>
          <tr>
            <td style="width: 69.48%; vertical-align: top;">May 30, 2024<br>
            </td>
          </tr>
          <tr>
            <td style="width: 69.48%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Page 2<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of the opinions expressed below, we have assumed (i) the authenticity of all documents submitted to us as originals, (ii) the
      conformity to the originals of all documents submitted to us as copies and the authenticity of the originals thereof, (iii) the accuracy, completeness and authenticity of all corporate records and other information made available to us by the
      Company, (iv) the legal capacity of all natural persons, (v) the genuineness of all signatures not witnessed by us and (vi) the due authorization, execution and delivery of all documents by all parties and the validity, binding effect and
      enforceability thereof (other than the authorization, execution and delivery of certain documents by the Company).</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As to factual matters, we have relied upon, and assumed the accuracy of, representations included in the documents submitted to us, upon
      certificates and other comparable documents of officers and representatives of the Company, upon statements made to us in discussions with management and upon certificates of public officials. Except as otherwise expressly indicated, we have not
      undertaken any independent investigation of factual matters.</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not purport to express an opinion on any laws other than those of the Commonwealth of Virginia.</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based upon the foregoing and such other information and documents as we have considered necessary for the purposes hereof and appropriate
      to render the opinions set forth below, and subject to the assumptions, qualifications and limitations stated herein, we are of the opinion that:</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The
        Company is a corporation validly existing and in good standing under the laws of the Commonwealth of Virginia.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Shares
        have been duly authorized and, when issued and delivered to and paid for by the Underwriters in accordance with the terms of the Underwriting Agreement and the Resolutions, will be validly issued, fully paid and nonassessable.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The opinion set forth in paragraph 1 above as to the valid existence and good standing of the Company is based solely upon our review of
      the Good Standing Certificate.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 69.48%; vertical-align: top;">
              <div style="text-align: left;"><img width="178" height="48" src="ny20029730x2_ex5-1img01.jpg"></div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 69.48%; vertical-align: top;">Insmed Incorporated<br>
            </td>
          </tr>
          <tr>
            <td style="width: 69.48%; vertical-align: top;">May 30, 2024<br>
            </td>
          </tr>
          <tr>
            <td style="width: 69.48%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Page 3<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We hereby consent to (i) the filing of this opinion letter with the Commission as an exhibit to the Company&#8217;s Current Report on Form 8-K
      filed on the date hereof, (ii) the incorporation by reference of this opinion letter into the Registration Statement and (iii) the reference to our firm under the heading &#8220;Legal Matters&#8221; in the Registration Statement and the Prospectus.&#160; In giving
      this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act and the rules and regulations of the Commission promulgated thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This opinion letter is rendered as of the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or
      developments that hereafter may be brought to our attention and that may alter, affect or modify the opinion expressed herein.&#160; This opinion letter is expressly limited to the matters set forth above and we render no opinion, whether by implication
      or otherwise, as to any matters beyond the matters expressly set forth herein.</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" id="z514a40e7ca584b46a1327abee6e1c61a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">Very truly yours,<br>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">/s/ Hunton Andrews Kurth LLP<br>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ny20029730x2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;">
      <div style="text-align: right;"><font style="font-weight: bold;"> </font>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
      </div>
      <img width="176" height="81" src="ny20029730x2_ex99-1img01.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Insmed Announces Proposed $500 Million Public Offering of Common Stock</div>
    <div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives
        of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to
        purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Insmed. The offering is subject to market and other conditions, and there can be no
        assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Goldman Sachs &amp; Co. LLC and Leerink Partners are acting as joint book-running managers for the offering.</div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">The public offering of common stock described above is being
          made pursuant to Insmed&#8217;s shelf registration statement on Form S-3 (File No. 333-272088) that was previously filed with the Securities and Exchange Commission (SEC) and became automatically effective on May 19, 2023. A preliminary prospectus
          supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC&#8217;s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this
          offering may be obtained, when available, from Goldman Sachs &amp; Co. LLC,</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font>Prospectus Department, 200 West Street, New York, NY 10282, telephone:
        1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> or Leerink Partners LLC, </font>Attention: Syndicate Department, 53
        State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.</font></div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these
        securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Insmed</div>
      <div>&#160;</div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed&#8217;s first
      commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious
      unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven
      protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements,&#8221; as that
      term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking
      statements.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The forward-looking statements in this press release are based upon the Company&#8217;s current expectations and beliefs, and involve known and
      unknown risks, uncertainties and other factors, which may cause the Company&#8217;s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed,
      projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risks and uncertainties associated with market conditions and the satisfaction of customary
      closing conditions related to the public offering; failure to continue to successfully commercialize ARIKAYCE, our only approved product, in the U.S., Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion,
      and amikacin sulfate inhalation drug product, respectively), or to maintain US, European or Japanese approval for ARIKAYCE; uncertainties or changes in the degree of market acceptance of ARIKAYCE or, if approved, brensocatib or TPIP by physicians,
      patients, third-party payors and others in the healthcare community; our inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that we will not successfully or in a timely manner validate a
      patient reported outcome tool and complete the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE, or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; inability
      of us, PARI Pharma GmbH or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira&#174; Nebulizer System (Lamira); our inability to obtain and maintain adequate reimbursement from government or
      third-party payors for ARIKAYCE or, if approved, brensocatib or TPIP or acceptable prices for ARIKAYCE or, if approved, brensocatib or TPIP; failure to obtain, or delays in obtaining, regulatory approvals for brensocatib, TPIP or our other product
      candidates in the U.S., Europe or Japan or regulatory approvals for potential future brensocatib or TPIP indications; failure to successfully commercialize brensocatib, TPIP or our other product candidates, if approved by applicable regulatory
      authorities, in the U.S., Europe or Japan, or to maintain US, European or Japanese approval for brensocatib, TPIP or our other product candidates, if approved; development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib,
      TPIP or our other product candidates; inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake,
      duration of expected treatment, or expected patient adherence or discontinuation rates; the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon Advisors, LP and our
      royalty financing with OrbiMed Royalty &amp; Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our
      operations under these agreements; our inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or, if approved, brensocatib
      or TPIP; risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies; risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we
      are developing for a particular indication; failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products; failure to successfully conduct future clinical trials for
      ARIKAYCE, brensocatib, TPIP and our other product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates or to
      permit the use of ARIKAYCE in the broader population of patients with <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Mycobacterium avium </font>complex lung disease, among other things; risks that
      our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected; the risk that the full data set from the ASPEN study or data generated in further
      clinical trials of brensocatib will not be consistent with the topline results of the ASPEN study&#894; risks that interim or partial data sets are not representative of a complete or larger data set or that blinded data will not be predictive of
      unblinded data; failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or Japan, including separate regulatory approval for Lamira in each market and for each usage; failure of third parties on which we
      are dependent, including Esteve Pharmaceuticals, S.A., Thermo Fisher Scientific, Inc. or the Company's other third-party manufacturers, to manufacture sufficient quantities of ARIKAYCE, brensocatib or TPIP for commercial or clinical needs, to conduct
      our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us; our inability to attract and retain key personnel or to effectively manage our growth; our inability to successfully
      integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities; risks that our acquired technologies, products and product candidates are not commercially successful;
      inability to adapt to our highly competitive and changing environment; inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology; risk that we are
      unable to maintain our significant customers; risk that government healthcare reform materially increases our costs and damages our financial condition; business or economic disruptions due to catastrophes or other events, including natural disasters
      or public health crises; risk that our current and potential future use of artificial intelligence and machine learning may not be successful; deterioration in general economic conditions in the U.S., Europe, Japan and globally, including the effect
      of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners; the strength and enforceability of our intellectual property rights or the rights of third parties; inability to adequately protect
      our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on us by
      agreements related to ARIKAYCE or brensocatib, including our license agreements with PARI Pharma GmbH and AstraZeneca AB, and failure to comply with our obligations under such agreements; the cost and potential reputational damage resulting from
      litigation to which we are or may become a party, including product liability claims; risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue; our limited experience operating internationally;
      changes in laws and regulations applicable to our business, including any pricing reform and laws that impact our ability to utilize certain third parties in the research, development or manufacture of our product candidates, and failure to comply
      with such laws and regulations; our history of operating losses, and the possibility that we never achieve or maintain profitability; goodwill impairment charges affecting our results of operations and financial condition; inability to repay our
      existing indebtedness and uncertainties with respect to our ability to access future capital; and delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and
      unexpected expenses associated with those plans. The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve
      risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company&#8217;s business, please see the factors
      discussed in Item 1A, &#8220;Risk Factors,&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent Company filings with the SEC.The Company cautions readers not to place undue reliance on any such
      forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any
      change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contact:</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investors:</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bryan Dunn</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Director, Investor Relations</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(646) 812-4030</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">bryan.dunn@insmed.com</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Eleanor Barisser</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Associate Director, Investor Relations</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(718) 594-5332</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">eleanor.barisser@insmed.com</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Media:</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mandy Fahey</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Director, Corporate Communications</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(732) 718-3621</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">amanda.fahey@insmed.com</div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ny20029730x2_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;">
      <div style="text-align: right;"><font style="font-weight: bold;"> </font>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.2</font><br>
      </div>
      <img width="176" height="81" src="ny20029730x2_ex99-1img01.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Insmed Announces Pricing of $650 Million Public Offering of Common Stock</div>
    <div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives
        of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share. The gross proceeds to Insmed from the offering, before
        deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $650 million. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional
        1,893,203 shares of common stock.</div>
      <div>&#160;</div>
    </div>
    <div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed intends to use the net proceeds from this offering to fund continued research and development of brensocatib as well as
        pre-commercial and, if approved, commercialization activities related to brensocatib, activities related to the further commercialization and development of ARIKAYCE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (amikacin liposome inhalation suspension), further research and
        development of treprostinil palmitil inhalation powder (TPIP) and any of the Company&#8217;s other research product candidates, and for other general corporate purposes, including business expansion activities.</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Goldman Sachs &amp; Co. LLC, Leerink Partners and J.P. Morgan are acting as joint book-running managers for the offering. Morgan Stanley,
        Cantor and Stifel are acting as co-lead managers for the offering. The offering is expected to close on May 31, 2024, subject to the satisfaction of customary closing conditions.</div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">The public offering of common stock described above is being
          made pursuant to Insmed&#8217;s shelf registration statement on Form S-3 (File No. 333-272088) that was previously filed with the Securities and Exchange Commission (SEC) and became automatically effective on May 19, 2023. A preliminary prospectus
          supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC&#8217;s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may
          be obtained, when available, from Goldman Sachs &amp; Co. LLC, </font>Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">; or Leerink Partners LLC, </font>Attention: Syndicate
        Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">; or J.P Morgan
          Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com.</font></div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these
        securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Insmed</div>
      <div>&#160;</div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed&#8217;s first
      commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious
      unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven
      protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements,&#8221; as that
      term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking
      statements.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The forward-looking statements in this press release are based upon the Company&#8217;s current expectations and beliefs, and involve known and
      unknown risks, uncertainties and other factors, which may cause the Company&#8217;s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed,
      projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risks and uncertainties associated with market conditions and the satisfaction of customary
      closing conditions related to the public offering; failure to continue to successfully commercialize ARIKAYCE, our only approved product, in the U.S., Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion,
      and amikacin sulfate inhalation drug product, respectively), or to maintain US, European or Japanese approval for ARIKAYCE; uncertainties or changes in the degree of market acceptance of ARIKAYCE or, if approved, brensocatib or TPIP by physicians,
      patients, third-party payors and others in the healthcare community; our inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that we will not successfully or in a timely manner validate a
      patient reported outcome tool and complete the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE, or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; inability
      of us, PARI Pharma GmbH or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira&#174; Nebulizer System (Lamira); our inability to obtain and maintain adequate reimbursement from government or
      third-party payors for ARIKAYCE or, if approved, brensocatib or TPIP or acceptable prices for ARIKAYCE or, if approved, brensocatib or TPIP; failure to obtain, or delays in obtaining, regulatory approvals for brensocatib, TPIP or our other product
      candidates in the U.S., Europe or Japan or regulatory approvals for potential future brensocatib or TPIP indications; failure to successfully commercialize brensocatib, TPIP or our other product candidates, if approved by applicable regulatory
      authorities, in the U.S., Europe or Japan, or to maintain US, European or Japanese approval for brensocatib, TPIP or our other product candidates, if approved; development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib,
      TPIP or our other product candidates; inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake,
      duration of expected treatment, or expected patient adherence or discontinuation rates; the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon Advisors, LP and our
      royalty financing with OrbiMed Royalty &amp; Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our
      operations under these agreements; our inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or, if approved, brensocatib
      or TPIP; risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies; risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we
      are developing for a particular indication; failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products; failure to successfully conduct future clinical trials for
      ARIKAYCE, brensocatib, TPIP and our other product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates or to
      permit the use of ARIKAYCE in the broader population of patients with <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Mycobacterium avium </font>complex lung disease, among other things; risks that
      our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected; the risk that the full data set from the ASPEN study or data generated in further
      clinical trials of brensocatib will not be consistent with the topline results of the ASPEN study&#894; risks that interim or partial data sets are not representative of a complete or larger data set or that blinded data will not be predictive of
      unblinded data; failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or Japan, including separate regulatory approval for Lamira in each market and for each usage; failure of third parties on which we
      are dependent, including Esteve Pharmaceuticals, S.A., Thermo Fisher Scientific, Inc. or the Company's other third-party manufacturers, to manufacture sufficient quantities of ARIKAYCE, brensocatib or TPIP for commercial or clinical needs, to conduct
      our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us; our inability to attract and retain key personnel or to effectively manage our growth; our inability to successfully
      integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities; risks that our acquired technologies, products and product candidates are not commercially successful;
      inability to adapt to our highly competitive and changing environment; inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology; risk that we are
      unable to maintain our significant customers; risk that government healthcare reform materially increases our costs and damages our financial condition; business or economic disruptions due to catastrophes or other events, including natural disasters
      or public health crises; risk that our current and potential future use of artificial intelligence and machine learning may not be successful; deterioration in general economic conditions in the U.S., Europe, Japan and globally, including the effect
      of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners; the strength and enforceability of our intellectual property rights or the rights of third parties; inability to adequately protect
      our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on us by
      agreements related to ARIKAYCE or brensocatib, including our license agreements with PARI Pharma GmbH and AstraZeneca AB, and failure to comply with our obligations under such agreements; the cost and potential reputational damage resulting from
      litigation to which we are or may become a party, including product liability claims; risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue; our limited experience operating internationally;
      changes in laws and regulations applicable to our business, including any pricing reform and laws that impact our ability to utilize certain third parties in the research, development or manufacture of our product candidates, and failure to comply
      with such laws and regulations; our history of operating losses, and the possibility that we never achieve or maintain profitability; goodwill impairment charges affecting our results of operations and financial condition; inability to repay our
      existing indebtedness and uncertainties with respect to our ability to access future capital; and delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and
      unexpected expenses associated with those plans. The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve
      risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company&#8217;s business, please see the factors
      discussed in Item 1A, &#8220;Risk Factors,&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent Company filings with the SEC.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press
      release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which
      any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contact:</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investors:</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bryan Dunn</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Director, Investor Relations</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(646) 812-4030</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">bryan.dunn@insmed.com</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Eleanor Barisser</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Associate Director, Investor Relations</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(718) 594-5332</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">eleanor.barisser@insmed.com</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Media:</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mandy Fahey</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Director, Corporate Communications</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(732) 718-3621</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">amanda.fahey@insmed.com</div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>insm-20240529.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<xs:schema targetNamespace="http://insmed.com/20240529" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:insm="http://insmed.com/20240529" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20240529_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20240529_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://insmed.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>insm-20240529_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>insm-20240529_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://insmed.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="insm-20240529.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://insmed.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20029730x2_ex5-1img01.jpg
<TEXT>
begin 644 ny20029730x2_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !G 7$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]C_\ @JK\
M0/'GAO\ :OO=-\/>-O%V@Z</A_X,G%AHOB36=+LA-*FI>;,+6QO8(!+)M7S)
M/+WOM&XG K^CCX=RRS_#[P+//))---X.\,2S32NTDLLLFB6+R222.2[R.Y+.
M[$LS$LQ))-?S,_\ !6__ ).\OO\ LG7@G_T#4Z_IB^&O_).O /\ V)7A7_TQ
M6%?K?'-*G#@GP[G"G"$YX"LYRC",93?U; .\I))R=V]V]V?P=]&C&8O$?20^
MEI0KXK$UJ&&XIR^.'HU:]6I2P\7G'$R<:-.<G"DFHQ34%%6C%;)':T445^2'
M]XA7\U/_  5@\?>._#7[3]OI_AWQIXMT"P/P[\,3FQT7Q'K&E69GDN-5$DQM
MK&\@A\UPJAY-F]@HW$X%?TK5_+Y_P5[_ .3J[;_LFWA7_P!*-6K]2\(*=.KQ
M=RU:<*D?[+QKY9Q4XW4\/9VDFKKN?Q/]/O%XK!> CK8/$XC"5O\ 73AR/M<-
M6J4*G+*EF=X^TI2C+E=E=7L[*^Q_1]\()Y[KX4_#6YN9I;BXN/ ?A.:>XGD>
M::::30K%Y)999"SR22.2SN[,SL2S$DDUZ!.?W,W_ %RD_P#0#7G7P9_Y)%\+
M_P#LG_A#_P!,%A7HL_\ J)O^N4G_ * :_.,9ICL4DK)8NNDET_?2/Z]X?DWP
MYDDFVY/),M;DVVVW@*+;;>K;>K?<_EP_9!^(OQ!U3]O?PIHNI^.O&6HZ/+\2
M_&MO)I-]XGUN[TV2")?$'E0O8W%]):O%%L3RXVB*)L7:HVC']2E?R<_L9_\
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M$]>O5J5JU;PZX.JU:U6<JE6K4GD& E.I4J3;G.<Y-RE.3<I-MMML_ O]K_\
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M#P>'Q=91>*J4<'#V^3UI?O<3E\*N7UX4<PRN=.O^C-?S ?\ !7[_ ).IL?\
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MC/V@?!/[-WPQUSXB>,KV$26MM/!X;T 3QQZEXI\0-$QL-'TV%V#R-++L>\N
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M-B:^$Q%'%86K.AB,/4A6H5J<G&I2JTY*4)PDMG%I/\]#SLWRG+,_RO,,DSK
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M)_)BBOV#_P"'?WPD_P"AC\<_^!VC_P#RFHKM_P!>^'_^?N*_\)I_Y_U;TO\
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M<W._[/!=:UJMIIUO+/L!?R8Y;A&DV@ML!P">*]'_ &4/VA_B=_P3H_:0\0>
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M-DUKP7\/?"'A?5I+'P[ILUF^HZ%H-CIMX]K,^MQ/+;M<6TAAD:.-GC*L44G
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M)!)<65I9ZA"715GMKN*:(O&X8DTW3IOHKI_/_A@.H_;@_P"3/OVEO^R+^/\
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M4L[J[C-L;;6[9%9I%<RI*"@4*S?T)_\ #I_]B'_HE^H?^%CXF_\ EC7X.?\
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M_J>GW%QID/\ 9\,\AL+.UN;^6>]E^USS6OV.);K]_P"BBLIR<I._>R\@//\
MXLV5SJ7PK^)>G647G7E_\/\ QE96D.^./S;FZ\.:E!!'YDKQQ1^9+(B[Y72-
M<[G=5!(_GI_X)#_ 7XL?#+]IWQ#X@\;^%/[$TB?X1^)M,BN_[=\-ZENO;CQ'
MX/GA@^SZ1K%_=+OBM9V\QH1"NS:TBLR!BBFG^[DN[7X- ?T&_%[X4>#?C?\
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(^=^7]?,#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ny20029730x2_ex99-1img01.jpg
<TEXT>
begin 644 ny20029730x2_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0K!W4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8U,NRZKB(-1=*,IQOWC&^OS/YU/^"D/[5UY\4/$,T'A3598K:*>2.:."<[2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)TX+:*>G3_+R?F5"K.&L6U_2_P C^0I?^" OA33IQ:K!%MYY$?7L/X<>W?\
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M (;N.E3KPIN%U>ZY7N^FG]?\/'+<!4W=1[?UY_E^M>6_$SQU9^$O#%_J\DR
MV\3OM+#/RJ6''7L:['Q#K-AHEE+/?SI @1B&9MHX7UQ[_P"%?A)^UE^TQJDG
MC"X\):9>&72;F22)VC<E,9V^W8D<G(.*^&X@XEI9;@JTJLTI<KBHWM+:U[=O
M/KOYGCY[CXY=0G4KRCR.DTHW][G:23MO:^JOY]7IVGC_ /:[B\2?VK8V\Y1D
M::%=K$=&*C!!]OH*_,SQ9XRU^_UZ[NX]0N@DDK,,2R8P3_O8_7IR>M3Z]Y=M
M,MQ;2;FNV+R;6/+/ACP...?3Z4Q-/M'@2><@,_4G'_Z_4>U?R-Q/QFIU:TY5
M)M2D[6>ROOTO_P  _ <SXC=&LJT:DOWDFFG)KJNFGZ_Y.'BC7Y].,(U"Z!((
MXF?/(/?/7W_R.'EO_$ZRA/[3O,.?^>TG?_@6?\\]:[U(;/:$B=23QQU./;_/
M%59[2-3O8 ,HXR/8?Y/7M^'QN"X[Q>&]VG6E&E*46W*3[KN_POH>#4XOK4JT
M?:5GR/6/+)[76^_Y>1ZY\$OBGJOPPOUU+4+Z:=&8/B25V'!![MCM_G-?IS\$
M_P!LVP\7^(K70S(JF1XTR3C[WR^O?'H.GX5^, 5;T&&Y)5%W*/< 'OTQ^6:T
M?"NNCP)KL>KV$Q$L4BL"K$<JVX8(_#\_R_1.&?$*<LRI2G6DT^13]Z]UHGN[
M?IW/>RKB^HL=1J.<FKQOK?W?=?\ 7K8_K0T[5HKZ&WFB</YD:OP0>",_U['^
MM=5'M= <<X_G7YQ_LA_&U?&^B0_VO>IYRQ1H@=\G/RCOR./6OT8M)8YH$DB(
M96 ((YR/K_\ 7_+.*_K;AK,99EAXUZ<TZ3BGR[O6WZ?/R/Z%R3&QQU!8B,K^
MTC&25]4K+=='W^99 QT%%%%?5GMA1110 4444 %%%% !112%@HR3BBX7&-M4
M9('Z_P JYS5=46W5B3@<Y)_3'/MS6E=S,%./3_/TS_C[Y^;_ (S_ !$TOPOX
M<U.66]CBO(X9#&I<*Q8 XQW!ZFOEN(LW^HX6I[.7+-1;4GL]/Q?X:]3PLUQT
MH49\DN7E3UD[;*_7OT.,^,GQYL? 5E.S3H6\M^-PZD?4=/3K7XY?&O\ :>N/
M&EQ=Z?8W,B%RX!1V&,G'&#U]O_U5Y;\6?CCXB\;:]J6GR2RR6J7,D2$,Q4IN
M(R.?Q/6O+K;0K$J+^Y<"5@6.?\_A]?U_DGBOC_&QK5:*K-*4G%<K_'3I]WRT
M1^+9IQ36YIQJU'*E3;TAOTUTOY,Q3=>)I7-U_:5WC<6QYT@ !.?4_KR,>M5[
MOQ5XB)6V74;LDX0?OI.O '\7\^>GI@]KYEEY)BB=3QT_3\QVING^'K6Z8S.!
ME6W#\.>#CGC(K\YJ<:XAPE!U:G-'XM7;371ZWZ6?RN?&8[BZ*C*,)S49?#K\
M.V^N^^_=G'^=XFT=(]7?4[O:Q#[3-(>!@]-WI]<XQ7W]\!/VMSX2TJWM+R=I
M'0("9&8\J><Y]\?Y.*^(O$4BO;?86_U:#:/?MD]./KUSSC-9UCI-O;:>TZ-A
M@,\<=OY_YQUKWN'>.HJK2G&I*+A4CS<S[..VNW^5NX93Q6J%2%>56;DYQ2][
MK=6Z[=>WK>Q_3#\!/C_IWQ.ME99HP57'W@#P#ZYXXZ?6OJN.Y60;E;*]CQ@^
M_'^?6OY9/@;\=/$'@3Q!8:?I\LH@FNDCDVL0-I;:>GMG(_I7]'7P>\9VWBCP
MII=U).DEW-!&T@W;CO*@G(Z]2?I7]?\ "7%M+.\#1C0FE5A&/M.9VYM(VLM&
M[^6ZOY']$<*Y\LWP\%*<?:1BN9-[Z+X5?[K?J>QB?Y@O7\OZ?YQSBK-4BJAP
M<C_#I_/UJTAXQ_G_ /77WE'$<SY)_%WZ=.K_ .#\MCZZ"G[W,T]=/)?U^:^;
MZ***["PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'T?AWPWIC[%5U@C!R.1A1G/XX]^U?-'[.7P(@TJ"WGU.Q$<J*C#?'SN"Y')
M[]/?K7Z'Z19"PMH[:)<1H  ,=L>@]?YX]*_LK@[ABCE>%HU:E!\\HQY%:SBT
MH[Z7^Y=DNI^T\!Y'5P"E5Q$6U.,73BTTX;7OUVMJ_+5FBMM\X;M^/KZ__K/U
MJ\. !Z4@R !_G_(I:_5L-1A1IKEC9R2<O4_3U%1O96N[O^OD%%%%=!04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML0JJE&I;W8^XTM>;3?0JW6HQPWD=LR@M(QP0.G/^?Y\UJ:C-'863&1=WFQG
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M.#H5ZM:?*KN2=^R^ZS\O^']D\6?%#1_#D+R7<R*(P2<L!PN<]N_TSQ7SA?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW;[RQ156WE,@!Y^GX?Y]*M4-.+:>Z"47%N+W6X4444B0HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=/?],U9?]L+QC?#*>(;X;1VNI><8_P"FA_R?4XK*AX8XBK";YJG-%[679/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M",@BEHH A2,J<]O\/I[U-113;;W)A",%RQVO?N%%%%(H**** "BBB@ HHHH
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MHKY$_5 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP/)3_P"M7O!&>"*_S]X@<IYCB^22NY^Z^VS?ZVN>+BHJ%><4M$UY=#P7X_\
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MCHIX:=2/-&UOZ_KY/RO_ *!/]I6'_/W!_P!_%_QH_M*P_P"?N#_OX/\ &O\
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M7'9=/'4IX6I%.C):.RO=+37\];[VMT_D9\9^%M2\%74MG<I+^X=E.01C&>O
MZ]\?AGI67HNI(@2>2!F&1U4]@<\>O^?>OZ%_'O[$OAOQE>7%W/'%NFD9S\@/
MWAGIMQW_ ,\5YO'_ ,$^O"\2B$11  XR$'J?]D?E],5_.N<>$V9R;JPA%\\[
M1L^[NN;;IJWY_(_-,5X>59SFHQO%MRAKU;VU_+T/PD\0:B;RX2:"%PB$%@%(
MQ@GTZ8'7->M_";X:ZG\5+V&TL(I0T<D8;"DY ;Z'MQT%?K])_P $^/"_W!%$
M0>/]6._T2O<_@Y^R;H/PLO/M=G%$27#\)[_0<<<>W4UEE/A1FM*MS.$/W<DZ
MNN]VMMN_];'%A/#K%TL52J5(1Y*<DY:]G'RZV/)/@'^S7+X42RN+RT'FQB,E
MC'\W !.3CKSU]^G!K]"M)6+2HX[94"<!> !CMZ8[?UK=LK"&VB55C48 ' 'H
M?\@\$BE?3DEF$Q[$$#UQT/;Z=*_>.%.&O['C%6_>2CJWT4N6^Z^[\K'[+@<N
MP^#I4O9JTXTU%K3?Y;=_N-*+E0Y_B'^?\]L5(3@9-(B[5"^@Q2D9&#7Z#&#I
MT^6GK);7VOI^AZ%[O7Y@#D9%+2 8&!2U<.;ECS?%;7U$%%%%4 A8#K_GWH)P
M,FD*ANM*1D8-8OVUYVM;[%_E_6OYCTTW\_\ @?\ !%!R,T4#@8HK6/-RKFMS
M65[;7$%%%%, HHHH **** "BBB@ HHHH **** "BBB@"O<2>6F?\^W]:XGQ+
MHT'B'2KBRN(EEBF1@RL,@AE(QT.?Y?F*[B:(2KM-0+:A$V]1SV'3W_\ UUMA
MZ]2A6A4@[<LDUWNFO/\ KU/&S/ 3Q_M*,U?#SI2B]KW:2>_S_/8_F^_X*&?L
M$7WCRWO-;\+Z<+<6JO=3&WA"EO+'F-G:OHI]^<X]/YGO%UO-\/\ Q+>^#[VV
ME-WI\CP.60[B5<KTP#GCC].E?Z./BKPS:>(-*OM-N(8W6[MY(3N4-Q(A0]?K
MU'/?Z_C7\0_^"1G@7QSXVU+Q9<6\'G7T[S']T/XF9^3Y9]3_ )Y']!\%>+U?
M*:<<-F-5JA",8P<?BTY4]5KI;3UL_+^5^.O YYSB(/*Z,6W4;K\[2]UV>GW/
M3L[G\?"ZS<Q:@DIAF\H'D;6P1GT[_B#QUY%7]=\0R73PR6\$JB,)OPI'3K^>
M/Y@U_5YJ7_!'GP'$&VV\& "/]4/R_P!7GKS_ (]*IZ;_ ,$?/ MPK(UO!AB1
MCRA^G[O_ ":_4ZGC?E=2-.I&K/V5.%GOO96W>MO\^I^3+Z/V8QQCPTL/%WE9
M/ITW_P [WZ;G\X?P8^%^J_M$ZC;>&-$MYA<I(D;%(VR3E1Z'U/'L.*_I=_8H
M_85O_A=%I=WJUC_I4'DN9'B&[Y><Y*]?Z5]"_LU?\$U_!WP%\2CQ%I]M 9?,
M5\>6.Q!Z%!Z<'/\ 7/ZI:;I=O9QI''"B; H^50.GT_3\_:OQ+C?Q/Q6?3J4L
M-5OAW=)/>VE_N\W_ ,']Q\/?!>GP_B8U<?0BJEDX\MFK:-7T]#+TM(])M;6T
M("E(DC'']U0 <=L'CG\JZJWRP#\@'GV_SV_$U6N--6=U<]5.?7Z#)YZ\UHQ)
MY:*@[#_/2OQS$585(QDFW4E\?K_E\C^E<#@5A5"FHJ-.DDJ:6E]%O]WKI9^<
ME%%%<9Z@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_(6VG8****@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!6O/^/2Y_ZX2_^@&O\ZC_ (+TPQO^TI*0!DWTV/\ OXWM^'^-
M?Z*]Y_QZ7/\ UPE_] -?YUG_  7E/E_M*R/U_P!.E/\ X^?\:^Z\/W)9Y2Y9
M2BWII?JU_7;4[LO_ (STOHK>O,D?C5I\4D=M%D$#:N,YZ8'\^OO4R,\;EG/R
M_P"?_KY_7%.M9_,M8L= B9]>0/;Z=![9ZTUG\\^7TQR#[ _AZ_S]:_T/X/C.
M.64U/WKP7/)ZM*T;:[_B>_%RDY<\4D[*7DE9?UVO<8WF23AUSLSSW&/;\\?3
MFEG29B-F>^>?Y?U^HI(YO*?R>N>,]?O8/I_G';K2W%[Y# 8SO_D21Z=_2O5J
M1@L4E#9QU?73E2_KJ6Y.G*+Y8\MO=NE[T>]^^VHLROY+8ZX/\N3TX&?\<<5]
M5_\ !-_=_P -0^'5&=_VZW ]1^_3_P"OQ^G%?*TDW^CE_4?TR#^A_P \5]5?
M\$WGQ^U)X<E]+^W_ /1Z#^H_Q[U^=<<J*RK$6?O)2]WH_=C;_@NW7Y'$W[]1
MQUDX>]%WM%::I='_ %V1_IB? 99E\':+YN?^0;9D?3R4_/M_C7OE>#_ JZ^T
M>#]%XQC3;3]88_;VKWBO\_<]O_:>*NDG[1[=]-#YZ7Q.VNNX'D$>O%?$W[6G
MP'TOQQX#\0:GIVGI+XB6UF:SF6,-*LOEL5((&<YQWK[9J&>WAN8VAG19(VX9
M& ((]P:\J,G%IKH[DG\J_P"RQ;?&[X)_$+Q#=?$"ZOH=!AU"X>U6X,JQBW1V
M(QO)&-N.G_UZ_6'PO_P4=^%%O>#PY=ZM;_VA 1'(AF3<&!VG()SU[^G0]:]Z
M_:&^ -AXZTVZM]+LXK6:XAD0R0HL;%F4KG*@'_Z_UQ7XQI_P28\52_$"Z\4I
MJEX(IYFD""X? RY;IYF,$'MQ7I7I5:474]W5;:7:M?H_G^N@O9U(QYK7B]F^
M_P"FK_3<_7*Y_;X^%=LNY]4M\;<_ZU._X_X\UYEXQ_X*-?"F72[W3+/5X/MU
MW!)#;@2IDRNI5,8//)'%?%6L?\$TO$]SB$:C=C*JN?.D_I)_D#IUKSP_\$E_
M%<NO:;J3:G>&.WNHIW4SR88*X;D>9TP#Q].IKDG"BHR<)MOIIOWUZ;[>?HS2
M?*E#EU;7O>3LO^"0Z/X$^(7QZ^(EUJ>IBXU#PK>79EMED$DD7E2/N!&<J1@C
M''O7[K_L^?#:U^'?@Z#2;2V%L%AC78J!>5![8 ZG\JS/@)\#K/X:^$M+TFXM
MHY+BS@C1I&4%V*1JN=QR<\9_GWKZ)6=8)!!&JJO P!Z8_P 3_C54I5)4W3@K
M\KYONM?SW^[I?8A.S4K;-?GL5GCN?,&,[<]?\\?E^?.3OP;A&N[KCZTY54@'
M'OWI]9U:WM%&+BDXZ-_U_5AR?-)RZOITV2_0****P$%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8&<XYI:*
M*2BH[*UW=^H#&D"=?\_Y_K5>\(-G<D?\\9/_ $&H[J)W(V^N>_KG_P"M^?XI
M<J5T^Y!_YX2#\E-:\L4HRYKMO5=MO\S1QBH1ES7DV_=[;?=OU/\ /A_X+JSQ
M1_M W@W8/VN? ]?F;/\ 3_.:_#O2+J:0$1Y9<G\N>W88[?X\?M)_P7AM+Q_V
MAKMXXY2GVN<Y521]Y@<GWQ[^_2OQ)\/:BFGILN$8-@@;U/4C'?\ /]>!T_J#
MPK]@L/AJKC&:A""FGW?+OZ?+R/:RVIRTY)[RM:75:+KYN_\ GM;7OY6B&X_>
MX!S^OZ?_ %_4:UAIUI=VIG.#+R?<=QU&?T]O6N=U.1;Q2T9 ![9]OKG_ .O[
MBI],O&L$5I7^1>HSCC/_ -;GMTQ7]*1S+!PPT7%4U-Z65MN6/]==_,])ZPY;
M;NZEY>[Z>O5>@:@MQ;2C8"-K#'T&,?E^6<8JW:7DUT!'=\)@ 9Y!Z#/../U_
M#I+-JEKJ1!C RIY'7T/T]<'K3+A!)%MAPK =NO? [^O^/K6N KPJUZ;@E%3D
MFK6][X>_]?KU4)TU"U1)..TGN[M?\/O\B#>@G\D']WD?3J!^?U[<5?,,2#"'
MY<#=Z<CD?KS]?:N?2"1I=F?FZ9Y'0YST_ UIEFMU\IR2S<#)^GK[GC_Z]?78
MRA"=&%YJ$E!.W=I)W^\*D6X?NXWO-2NM;NZ^]C;H)'@P$;CU_'G\/I4P6/R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[%00<>G\^O(_QJQ1>^Q4HRB[-6NK_>%%%%!(4444 %%(2!UXI:5U=J^JW78
MHHHI@%%%% !1110 44A8#J:4'/2I4XMV4DWV]-P"BBBJ **** "BBB@ HHI,
MBDVE9-V;V\P%HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44R1Q&I8]*A@
MN4FSM(X..#_GO_2@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7]:0KDY[=Q_G_/\ 1]%3["G;EMIS<V_5#N_T^04445J(**** *-Y<F#&./\
M]7^>]36TOFQ[OI^M)/;K/C/^?\_A4D40B7:.G^?\_P#UJV;I^R22_>7U?W>7
M]6 EICCC/I_6GTAY!S7/**FN62NF-.S3[,R+FY)@N4YXAE'4_P!QO\#V_I7^
M=1_P7LO_ /C)M[?'+:C/S@XP78?H0/Y5_HMW4:>1<MCYC#)G_OD__6_KFO\
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MGKW_  S7Y'-SO#E2:O[_ *76WWLXRDUZJR^7D=<>OM_A_2K1C23#$9_SSVK
MU6>QTI&O[^XCMK>/+-)(X15').2Q ^A/_P"KBC\:_AM"QB?Q1I2NA*E?MUMD
M$'IS(#QTZ5UU(1<8>R4F[>]975]-K+7[_/N"N^GW?UW/5BBXY& /\]Z4;5&
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M )S]/4UL5YAB%%%% !1110 4444 %%%% !1110 4444 %%%!YX]:3O9VWZ7
M0$'I2T@7;0Q 4EN  <GVJ:?-RQYU[VETM?Z8%+[8OF^7D?\ U\X^OX>M6FE5
M>XQZDX_G7GVL>,O"FA3N^IZO96NS)/G7$4>"#WW,/_U5\>_'G]KWP;X)TK4;
MG3/$>G2RV\3E1%>P,25W=-LF<C'8=:]G"996S"M3HX6G)RE&][>ZWI?77O\
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MN9(&O+;=&V&S,O\ //\ G\>-OPM^V?X.\1:@EC#>6P=R%_UR]_H?IZ]_>O\
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M3Z'\&?MK?M!:=\0/!^G:?K^H):SZOI\,B+-<8*--&I'$H'*DCICN,U_I'_L
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MKG;E%RB]E>U_NVTZ[HSK=)8RXD)Q@[<]\XQCWX_G2+N$I\S)3)QG)&.,\?\
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M *WYC;#2G3K5$ERM25U;;X?F=2A"3JZ\C4E:?\OPZ+\4MEYBATO&^RW!Q&,
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MZ-I:J_W_ '!1110M$EOY]R0HHHH **** $  Z"EI"0.M+41Y%[D;+EWBNGJ
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MFZDIRC>R?=)R?IHWMMW S/VWOVUM!^&NBWXT#7K87D%O,=B3@,)%3T7G.?\
M(Q7\4G[;/_!1;XF?'75]7\!:C?W,^B-)/$O[YV0HSLN<<8& /YUQG[3?[8GB
M'XH>*==6WURZFM9;J<1IYY9=CMP!SCMT].Y-?"+P_P!HWC7]Q^\G<DLYY)R<
M\DX/)S]*_JC@;@"A0I82I6PZG6IRC.-24/>OHTKM=%IY>9Z6!PL:S55S5H--
MQM\5K:?U^5S%TGPY#"&0E\3,68$G&7Y/<^I^OO776UE;:&N;?:"YSQ[_ )'W
M/7/UJ 7"12>3_$3Z_0?7KC^7J*BU,RKLR3\W []0>GU]_>OZ*PF3J$*:2Y&T
MG>W:WKZ'LPPZJUX2A[D8:MK;2VO?IUO;<M7=VTRY0Y)/0>O_ -;\N>,4EM#;
M2)FY*J_/!Z]#_+@'Z5%I-LSN&DR5ZX]LY_PYJ+4M+NYY_P#1R54L>!W_ /K@
M?RSCBO>A2^JQ34>:HE;F\M%OM^74]%2]G!S3=:2?*Y+=)+YK^G\M)[:R>-]K
M(2.F/H:Q+;2XYKE@X^0'CGK_ %]/\@TO]FWUD,S,<<$YZ8]_U_.K=K=I(VQ3
MAQUYY]1S_CZXZ=7*O:"TOS?%'[G\OFNGI?*5>#C&3BI/JGTVO]^G_#Z&EY*6
MJE%X3'3@?K^7O7/WUQ*)0L62I."1V'/\N/\ .*U[EF,>T'YMI_S_ %SS^E0V
M4*EL2@%B2!G'ID=<<#T_*E4GAZLJ;]M&+@DW"][;:=EM;KTN<BA>,I[-R]V/
MEIJO3OV]-$2V@"*\I +#G/\ +C_/?KFFFUBAS-#\QSG@?X?E[C/%6M3TJX>-
M6B) QV[#.?\ /^%1VBF&,1R\D==W/KGZY/7M3IYG0]I&#Y;)I23=]%:_^9*G
M/G5Y-N#C+DWM:UKOJAB;+ECYWW^P)Y/;I_+IUZ57OK98QN';!'\\CV__ %]J
MANU=+@2IQ&#GKQU_+^H%6;B[2^C5$QN3@]>N!GL>3Z=?USWK&4.9^SE&4'\4
M4[KR7X=]T_4Z:,YSJ.I.?(HM)0[[+_@[Z?>/TW4"'\ISA1T_/]<<]*DU"\W2
M^4IRC$]/0X_/UQQDXJE;Z;/*X6,\@8X__5[&G2:?/!*/-Y/'U_P_S^-<=65*
M2GM):N,?R2_I_=MV>UIJ,FIJ]M]/P5_Z_*W! D8R!RPY_'K^/OQ3)42,[X^6
M/7'^<<>W]:G^Z@!ZX(%4U1HI-[_=)X_3CGU]*PRJJIU&N7WD]8VV6FOZ?,\^
M+DY2DY7\OY]5HNEB6%$?YW.'&>V",=/S'Z>U2R10,?G(!'0<C/7\OY555'DE
M#IP@QTX'_P!;D=.W;DTV[MYI'4ID =?S/IT_I[5V5=<7%<O*N5JW_@/]=/(5
M1N,DXSUWMK[FWN]NO3J6Y50Q'IC''3GC'X\=A_.OJC_@F\H/[4WAQ3]S[?;Y
M/;_7)_GTKY1D1Q;%?X@.?^^2.WX?3%?5_P#P3?Y_:@\.QCB0WUMS[^?'^)[U
M^>\:1C/*L2I>ZHPFU4T_EC;R\_\ @')-W<_L^Y\=[<][>[?=]O3\?],OX&Q1
M1^#M$\O!SIEIGV_=1@?S->YUX+\"(I8_!VB>9G_D&VA'T\I>GK_D]S7O5?Y]
M9_IFN*]_G_>/7T/GI?$PHHHKQB0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *_G9_P""],S0_"+(_P"?.7]5GS^G\J_HFK^>
M+_@O$B/\(OF'/V.;^4Y'Y^_]*^IX+=N),LUM^^6OS7]>1TX248UX.:YHIJZ^
M:/X+[Z5CJDCD<^8W!Y'WL?CC.<_C4DZB7$IP"O..G3T_^M_^IVIJD6K2$D;=
M[_S/\N/ZU2N[@--&L1!4GYL9R1Q[_AFO[^X=]K"A3FDU&T=+7OMJNZ_ ^PI1
MG4CS4Y<D+Q]WRT=K==/F7X;IYE*$<+QDCT/^/]:IB]?[08-O&>N..N!_GZ=Z
MV$BB6)77&<9;CU/.?0BL_P#T?SNWF<>GH?TSFONU&#I2J+XI1U?_ (#IY?K8
MX\3+]_H[]';7HO\ +?R(+BX>.38!D'VXZ\?_ %^14$S'SH3C^->@]P/S]*UB
M+<CYP-XZ=,\FL>[FCAN80^ "ZD9Y'WACOZFODL?&K*+Y>:.CM+HE9:_,WE",
M*=&2T<XWEZZ:_.Y_1#_P167/Q@TL\_ZZW/\ X]_]:O[SK+_CSMO^N,?_ *"*
M_@N_X(J-O^+^E,I)!GM^F>FX?Y_&O[T;+_CSMO\ KC'_ .@BOX@\7;KB2SU:
MI:O>^I\OC?XS_KL6J***_*3C/S$_X*N:;>:M^RUXSL[.%YI9-.N]J1JS,3]F
ME &%Y/T[U_F8_P#"$>,=&\8>*%DT:_5)=7OR"UM-R#<R]"5[Y_\ KU_K6_&7
MP!IOQ&\'W_A_5+=;FVNHGC>-U!4AE8'((([_ -.]?@I\5_\ @F#X#DU"]N]+
M\,0;[B>64LMLF26<DYQ%Z\Y]><5^G<!YO2RU5?:5%!2DFTY)=$KVW_KI:YU8
M:482<Y:VTM_6O]7Z'\'5_'XC\/,+E]/NDWG.#%)T+?3'_P"KWK7MOM.LV8EN
M(G1VZ[E*\]>C8]O_ *_;^JGXU?\ !+R:YLG&D^%R6"-MV6V><GTB[9SUK\Z?
M%7_!,WXM64LL>F>&;I8E)"[;>4< _P"S%W[=17[7D_&^$H4Y1^MTXI*^LTD]
M5;K\_35W/45?]TYQFDKWY;]4UW[_ )GXN&8Z(WIMY_7Z>W/\Z5M>&M$1,V-G
MH0.Y.>_/K^E?HKXL_P""9W[0$[OY'AK4"#GI;W'O@\1_Y[<UYNG_  33_:)T
MM+B\D\-:BD,"-*Y^SW& J+EL_NL# _P^OTV5>(^"J8FE">+IQ4&E!NI'2[6W
M_#^NNAI3Q,'2<YR3<E>U]=+=/+^O+Y(E519^6N"1CGDY_'M['\/6LVRAD6=
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M(_$'#1J2A&O&":2YN=)7TO\ BE_D<]>K!--N\;_#=:;:[_COY'S%>ZZ=+79
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M ?NN.>#UKZ?A;+JF:9MAL*H.5*=1*H[72U6__!V^\VH*<FX1O:6CTT_JU_\
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MXU_F*_#Z&U'Q-\)!P,#7+';^%RF.WZ?AZ5_IW?\ !/#:/V:O X3&/[,M,?\
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M[GU)_P ^M9$5QJ7B+Q#<^*-<9Y;J_D,TLKDDLSDL22<D]3SG\?3K$@DFG1Y
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M_P"09:9Z?\\DQC'XU[E7^?F?6_M7%<L>5>T>A\]+XF%%%%>.2%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\\7_  7A7/PC
MSG'^B2]_]F;_ #^=?T.U_.O_ ,%ZY'3X0_)U^QR^OI/S7U/!B4N(\M4MG65_
MO1U8.+GB*<8V3<EJ]OB1_!]K<9EU.5 0,R,,_C_7!%9+6SV\Z!LG/0DY_#.
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MW5M9LC.C&&4B:(.."K$'<O3Z_GUK^BWX7_LY>!_"_A^UT^[\.Z<\D4:*2]G
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M\.?"C18+/6-#LIY$@5,S6L+'(0+U:/)Z$GCZX.*^WQ\)O 0&!X=TS_P#@_\
MB*]$C554;5 ^@_#^525^.8O,,3C<1/$5:DG4F[MIO?NNQYDZDYR<FW=[V_KK
MN>;-\)? 3#!\.Z9C_KS@_P#B*\K^)7P!\$>(/#VI:9:^'M.CENH'B0I:0 @M
M](Q[9_SGZ=K)N2=ZDC(SD\?YS].E&$Q>(HUHU(59J4/>7O/=--=?ZU-\)4G"
MKS1>JB[7^1_(+^VY_P $:]:^(@US7-(M7ACC6>[ AB"C:@9_X% Z#&>X^AS_
M "?_ !=^%^L? GXAW_@._MIU;3YI(F=U;'R,4ZD?[/![_6O]:S6='L]9TN\L
M9H8W6YMY86RH/^L1E(/3J#_GD5_(_P#\%B/V /!WAOPWX@^+5A81+JDOVJ?>
MD04@\/U SU8]:_9>!>.,=4S.E0QM7>4(0Z=H]^RU_'L=6&J0EB+U+^TEIU2W
M[7T7W?H?R)PQ>?*DHQC@_3.?7T^HZ>Q-:][/'%$B'!. .W7^O8GCL#SBN.TJ
M^DCENH)3MDCFD10>#A6( ]L=_:KMU+*S*9<@94CC'? Y_+KUK^T\FQ<\5AJ$
MH334(+F3WE?EV7I>]CZ:FE4A.G4LXQT5][*VW^19N;201?:%)P>0!G'K]?Z]
M_>LV#S)9!&2V#V)P.M=CIQCN8EBF/R=.?ICO_G],U-0M(+5R\'.TYR/H3^?U
M_I7I_68J2LG=-:VTOH_ZTZ?<EB*:M!)M:132WVMK_P #[A\%DL",[8SU_/O^
MOU_'BL#5!]L5HEQQNQ^7&./_ -?>K(OIYE9%!(Z?KC\>U01*=[D_>QTX[CO[
MY/>NW'T5B,O=6UY1AS27?1/336^O]6,Y4/WE6I+9I<FVFBLW\_ZV/KS_ ()C
M7VL67[6'A"T6\G%O_:%MF,2/M(%Q%@;<X_S@\5_J%?#LD^"O#98DG^R;')/7
M/V:*O\P7_@FVT$/[6'A&65E7&H6V2W8_:(<Y_P#K=/?FO]._X9WMO=>"O#?D
MN'_XE%CT/_3O'_G^G7'\">-,6\ZH24)<JIS3=K*]UOZK^D?*8SVGM7S[7?+Z
M:;G>*I!)_"GT45^)0@J:Y8WM>^NIR!1115 %%%% "$COC\:3:HYQ[YJE=22*
M1M]<9_'&/\_UI9)BEG-(QP5B9O3!"DG\O\]:MP:C&5U[W3J:.$E",[Z2TLGK
M]W4^,OVZ/']OX"^!?BK6_M:0S6MC<, )-K?+!*W&"#[#WK_-V_:E^-]Q\>/'
MNN)+<R3K8:M=(-[LV!%<,!]XD#IT' ].E?T<_P#!93]MWQ1X<\0:]\+(KUX]
M.O3=6SQB4JN"K)C&#V)ZDC^G\C<J21ZS?ZE:;I&O[J6XD*_-\TTA8DYR2<M_
MG-?T?X19![JJXJFI>VE&I1:5^5>[HWNG?U/5PU*HJ:3LN:S3L]$UU;>AT$]H
M@LXK6-55D"KD#KT]O\_@:U) L>AO;@?O2N W\0.#WZ\9'-581(\8=E/F8)/M
MQ^OZUGS7,WF>2P.T_P O_P!?Y=/K_5.$B\-3AAXIWC9I[K96U[]%^1[&#HTU
M+WE[D5?UDK7ZVU]?P(?#(EM_-$Q9LLW7GZ8YSQT]AS3]=( 4Q\%O3KD9ZX]A
M_P#JKIK""R2UD8LHDVY XR3^ Z__ %L=JY&4M<W4BR9\M6;:>O /'4?TY^O-
M=]6O/DYJEUR+6R_K5[O\-$*M5=6>_+&/PZ6M^5O^&-2S39I_GL1G:"<\_P#Z
M_7']:T?!'@;5OB=XOTOPOI\4\G]I726X:-6/WVV]L\#(].G7ICG(K+6O$$ZZ
M)X?MY+RZD8(L4(+,220.%[Y_#^O]6G_!&O\ X)R6WC32M.\;^/\ 1'M=2LO*
MNX?M5MABX,; C=G.<GH*_'>/>,J&382LZ]6\W_!C!KF5](WC?H[7^\\JMBXP
MC*E._M+IQ:U7*K:77R>^I])?\$K?^"5ES\)H=,\8^)=/6ZBU..&\4742N,/M
M;I(I![]O<C%?TS>%OA9X3\-V\/V'1;*WEC50'CMXE88 ]%!SGTK:\,^'+7PA
MH&FZ)8PHD-A!% @5%7 08SQWQ_GFNPB<^6">I _ GK_D^U?QWGW$N89M*5;$
MUFX<[<%%M-J^ETGVMVZOR/,GSRM6<MWMLUM\O74+>%85VJNU?3&/3M[58IJD
MD<^M.KYJ,_:)3U][75:F#;;U_K[@HI@)W$=OY?\ ZZ&8AO;^=8^WCR\UI6YN
M7;TUUMW_ ,PM_F4[S3K6^4I<PQRHW!#J&R.^0P(Q^M?-OQC_ &??"?CG2+JW
M70K!IYH)$+_98BQ9@P!R8\]6'?MCL*^GF;IC_/M3L9Z@?0\UZ&7YI7P>)A6P
M]249T&I1U]WH]MO+_ABHSE%II[=/Z_ _@[_X*9?\$F]>\*:CKGQAT^TDCL+3
M[1<>5#'A, %Q\JKQ]WT]:_FUFOIQJ%UILT#P/97$EN0RE23$^WN!_=/88K_6
M6^._P:T3XT^"K_PAK-M#):WL4D;[HU;[R,OIZ'KGO7\ W_!7']C;0/V:/B"\
M?A2R6**\OW>0Q(%'[QV8],>I]!7]%^'7B!7S#%4\#FDI5*[M[&4=$H*RU^_[
MMG<[J%24Y13NY-Q:L^B:OVZ:]C\AM&T]IBQ).#T^O/U'/KSS[BGQV;V>I"21
MMT8.0#RO;MT[T7-X^G6,+0C]ZRC<!U!X^I[U)8M<7L:S2J<'!).>O^?IT[5_
M3^"QWM8PNFXM+E26J=ENO/\ IH]Z7-4<+M*5HI]MDOZOY]BQJL"WLB2Q851@
MG P">>P^O\O2I+:R,\9&1\@_SU'M_P#KJA=2RPRJB [2>3Z<G_#GBH+G49K5
M0(<DMP0.O(P<9X[^_N*].K1FZ3:NO:)-76R5OT\M--S;$+DA0CNXKWFNOP_U
M?S,#5H1=71LU'*.>1TX(/;G''\SS7[:_\$O?VP1\+/'?A?X=27)3[;=VUOMW
MD YEC3&,]A[>AXS7XUZ79;YOMEP"I8DY(]O\_P"->P?LXW=CHW[0?A'6I+A8
MHK;4H)"Y;"KME0^W3'Y_E7X_QQD]/$X3$7@N;V<K.2TYN7IIOY'%B4ZE/DE9
MT]]M;NW^5S_5.^&.LIKW@?P[JBN'^V:=;39SG[\2'\Z[ZO@/]BOXQZ3X[^'W
MAFPL-0ANWMM*M(F6-]YRL07'?T_D:^^D)(Y]?\*_BC,L'4P.+K4*EE*,Y:+M
MNOP9\Y6I.E-Q;3ZZ??\ J.HHHK@,@HS152\=DA9EZC_]7]: +)=5!+, !R3G
MI7XV?\%4?VMM-_9\\!W4YO(P]U93( L@R"\4B\C</RZ].Y&?TN^)GBR?PSX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[))]+N8U&[!R4/T)^G7'Z_YN'Q8O/M?QL\97\QWQSZK<.I/HS9ZX^M?W$?\
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M>"IJ--P6EU=M:WTOZK\2N:,$]_9IW3M:\U;1]+=]7Z7.;MK>^NRTD+-Y:'+
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MK_.2_P""]UO.W[3[R<F,7\V>W_+1L_IG\\5_HW7G_'I<_P#7"7_T U_G2?\
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M,*ME*Z;YOM=D]+V?5;FA;21>6S, 5P3TX[G'MP>W]!7U)_P3G"C]JGP[(/\
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MQ]<=6/'IU^OIC-7C_P 2T*TI+!B.#TYZ=LC\NN/K7V^)K22D[\THM:/S2O\
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MNON?YUGM*UD23SN)^F,'C]<_KBLRZO/LCB[D.49AQDX[#_/?KV.*XLWQSP^
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M?]<H_8?Y_3W:O\_L^DY9IBFX\O[QZ>9\_+XGZA1117CDA1110 4444 %%%%
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MWN[=^O\ 6AY<V^52Y[NI\44[[6W^?0?UX-(!C@4M%</+%R4K>\M$S$****H
MI" >M+12:4E:2NGT :% Z4ZBBE&,8*T4DO(+F3KD2S:7>(W1H7!S[BOY#?\
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M_LL_X(X?L$^#]:\"^'?C)<6L8UA4M;C>8QO#8W_>QZC_  K^J32M/6VL[2U
MPMM"D2CD<1J%'TZ' ]/IBOS&_P""2_A&?PE^SGHNFW,;1LEK:C:1MZ1MD8.?
M\_I^K"J%Z?Y_*OX8S[,L3C<QQ,J\Y2E"K.$.;7DA=.R_K[]SQYUY7FG=3;WV
MLM-/ZZE2XM%G4*V./_U=?\FIX(A"@0?YZ_XU-17SYRA1110 50>R5I _'7\L
M]?SQ^':K]%7"<H-N+LVK (HP /05%+$)1@_Y_P _ATJ:BI3:=UOW&FTTUHUJ
MF0I'Y:$8['W_ ,]J_C[_ ."^>EK>:ZC%,@/W!(QQW]<C/TQ7]A)Z'Z'^5?R2
M_P#!=KRSJ3%@,C/7G_\ 5G_/2OJ^#%SY_A>97O+6]NZU_#^F=&&<763J6LUJ
MWM>ZMT/X\;JRBM[Z4+@'>V0/U[Y/H#222[(R5/S 'C/OZ=._7VJ;5$D36+K=
MG:9#@'\,=/H3Z56^RRNY?_EGQ^1&?PY_^MFO] >%J$8X&C4C-2<*<9<O:RB_
M)K;[KJQ])0I1::34HQ]^_1K9K\.]MO0N6<OF1L[GYATSR>#VZ=3_ (5GSB2]
M=DD'RJ?EST_B[^W3'TZU::WD!#H3MXW#MV/ZY_"K@,4J;4'SJH#GZ#)[>I_H
M.>OV%6,7AU5B[SJK5):JUK7_ *Z;G8U&>'DX0Y7*RLNMEMY[?B0"-3 +<_=P
M!UX[^O3'MU..E83+):W*1Q9\L_>[@<]_ZU=NKU8R8LX8'M^''3\>M6K>>W-J
MYD&Z3'RGTR/Y=ZXL1/DRJO4D[SCS)1[:;_)K2_F>=6<H4O;2=[-4[;]4OP_7
M82RFAF\1:#IC,NW4;^TMY%[8FF2,Y'8?,?KCGCK_ '1?\$I?^"?O@?PMX(\+
M?&*TMH?[5O8;6Y=Q&NXL8HY,[O<N:_AB\ >"M9\5_$'PN]DCND>MZ>WR@D86
MYB/;_/'M7^G#_P $VM'GTG]F/P38W0(DCTZV# C!S]EMQR#G'0CBOXL\5,[Q
M?-"DJTU&=6<:D+NTHZ:/UZKMMUOY>,G^ZC:34I;I/IIWO?\ X;L?>FG@K!''
MC 1%4<=E  _*K]-50@PHIU?@DGS2;2LGT/+5^HTH#SS3@,<"BBLHTX1;E&*3
M>[_KT"["BBBK **** "HIO\ 4R?[C?R-2U%/_J9/]QOY4UNO5?F!_&;_ ,%L
MT63QO?JP&#).#Q_UT_$?R_4U_*K=01V^JW;)CF9\_G[Y_7D<G S7]4O_  6X
M8CQM?X./WD_Y_O?\_P"17\IDKNVIWH8_\M7('7N1VK^Q_!#$MX&$8Z.*@K_=
M_7]6/?P]"+I4ZJ2C9+F\W=:V\M/0T;F[_=A4;) QV_4<]/\ /K5!($N!N?[Q
M).#GGW_$C^7K1%!(9LN<KD^_'^<_SJ26-XY/,&1&,9YXQZ''7Z?0=:_J.ERU
M*/)*T9<O-SOO;?U;U^9Z2DKJ"FG.W,I_=[O]?<1&TB0@MCL0,X[?G].1Z$U-
M- MQ%Y?50IQ_G\_QJA=M)<L@B)X/S#/IUS[]<_7FM&)'$*J?O!?F_ 8(_P _
M3I7CXCFH1?+4]HW?W%?6]E]UOUZF,I3D^6I>Z?7HG;7YVO;_ #-GX>Y@\36D
M*C">8F2!Q]\#^6<')Y[>G]V/_!$P1CP:-I&?LJ9Q_NCW^I]OY?PJ^"2C>([5
M!_K#(H!'!Y8'M]<_H?2O[G?^"(<,T7@\&0];4>^?E&.O^>/<U_*/C-253"U:
M[CR.,DK/XG[R?]=.USSL<HNFWR6DK^]W^'\?ZTL?T4T445_+1XH4444 %%%-
M;)4_Y[T >7?&'4[.S^'WBM;F54WZ+?@;B!G_ $:3U^OU[U_F%?\ !0>"SE_:
M=\:W-NZOOU*Y/!];F?&/S[\X_3^_S_@H5\<[3X7>#=8M[J[^SFZTRYC'S[<[
MX64#'N&[?@:_SI?VE/$,OC#XX^(M;65I8+J\F96R6R&GD)SS[_\ UZ_H7P<R
M/]]+'\ZE[517+_+9K^NW?L>IAL/)QO%\RFM;;+1/U9Y+:6BDB9QC'/\ 7I79
MV=O:W<3&1UW1@XS@],_Y/7Z<5C3V,@L6F08"KV'J,_TZ\^U<]ILUT\S*C-M#
M$'GT/]/3V]17]@9/4J*])MRC'2W=KE7FNK/8ITU%TX\W);3F[6MMM;\$:NHR
M2M*T"@F-3QZ8]O\ /3KTK5BG8V!M3P",<\YR._X=NU75LEDB!."^ 6. <^IY
M_E^59C,JR^1CDY'Z]/7J/KZXYKVZZ3PDXNGS.3<5*WPMI:_UV?9'3B>>7+3B
MFTDGS)7YKN_X_P!:W,0V*0^8,##DYYXZ_7TXK^AC_@@]XL\*^#?BG+<ZS?VU
MHOVI&+2R!,8,7&3^72OY_+_$<+ISN=>/J3V_EU_PKN?@I\6?%'PCUJ34M,U&
MXL=\A96BD*>F,$>X&/IZU^2\;<)SSC*ZF"C[CKP<75L_<O9W?]>NVO/4A*5*
M5.5X<Z26^RL]/N/]2(_M)_".$IN\4Z6K!5X^U1Y''3J/Q'7\#4@_:@^$7 'B
MK2_8?:4^GK7^;EJW[:GQCN]UU;^*M3\KMBY?& /J,_IFN9A_;.^-COYO_"5Z
MF57D_P"E2=/INZ]/7\NO\OYAX48S"SE!8B55PORKD>J7I>VUOO['EU<M<7"\
M^:+2U[7:T_/T\]S_ $NO^&FOA*<'_A*-,YZ?Z4G/>D;]IOX2JNX^*-,'_;RF
M*_S:H/VVOC"R!/\ A*]1RO7%RY]1W/KQ^M0WO[;/QAFB\J/Q5J6\ 9Q<R=^/
M7^?XUX=#PYQ]2;A+GBUWBU?5;:(AY8U]N[23:UT^'\-^^_H?Z2K?M,_"2:,_
M\53I>!GG[2G^/M_GO7M?VDOA$C%E\4Z6><_\?,8[Y/?OZ'\AP*_S:K;]M7XR
M10-$_BO4_,(XS<OD9_$\?GWI]G^VI\9+<N9O%6I?-G;FYD[YQU/^1WX./4P_
MACC9QE&5>4%IHX[[=?5^NQ#RYW5I7NKK3=63=O+_ (!_I.C]I[X2%]O_  E6
MF=3TN8\^W>I/^&FOA+G'_"4Z9_X%1Y_*O\UF/]M/XS)<&9O%6I>63Q_I,F",
MGU/^?;M?;]MGXQ$^:/%>I;1_T\OZX_O<=.O'H,=:RJ^&&+ISY?:MJRL[;NZT
MMYZ_?]V<\#*,5)2NN91=NFU[WVTN]S_24D_:=^$B$ ^*M,&>QN4S_.G_ /#3
M?PEP#_PE.F<]_M2 ?A7^:I=_ML?&6ZD5H?%>IX4C=BY?].>W/IZ@CMHQ_ML_
M&%HEB'BO4MP&3_I+_3NV>_K_ (UBO#3&7LZDM-9>Z]%I;MOKKYZ^5RP#5.4X
MSYN57=O.W_!^\_TF'_:<^$B)O;Q3I@'J;E"/SR.W-5E_:8^$5ZK"/Q5I;YR.
M+J/K]-Q/^?3K_FR:E^VW\8Y+5[:/Q7J8EX Q<N.HQZ^_3.>WO4_A/]L?XUVB
M/+>>*M3*C)YN9!Q^?<$D=O6N_!>%6,Q$TO;RAKH^5^6OW_UM90P<K1E&5Y.S
MY;:INS2[7U]-C^BS_@X"^)/@WQ)\-47PYJEI?3-;-\MO(KDY\WC SST_3UX_
MC5\.+*\/F/G))ZCT)[#]._ZU]8_&?]HCQ;\7K$:9KNKW.H*@*>7-*T@Z'(()
MZ9)_+-?.]O;I96G3;@] /\1^OUK^C> >#YY3@J>"KU?:5824U4:UL[-):?=Y
M[:'3"%5.\VVZ=FFUOM:/]=M;V1U=K#$UE)*2I=5./7.W/KU(KF[:ZD:>5'^Z
M"<>X&.F.G<?RJU87#SQD*3M(P?Q'/!QW&?Q_*2>Q+?/$.1R?? _G],_3FOV_
M+,'5IQY)0DHV7OVTEHORM_5SLIOV[A>T92^R^_;[[7_0PY+-9;EBWW"?0D<9
M]^I_J/I6REO'% 85.5.,G/U_ECIV^O-02 !/+ Q*,9YZ=_Z^P%0F1HX3&Q_>
M'..?RY[]NG7\:O%PJ4H-*[;EVW3L=,Z2?O*/+.%ER]7:WO=K/L_,PM#A2U^)
MO@YH2,G7-/SCKS<Q_P _P_J?]0[_ ()JL6_9=\!D]?[,M?\ TEMZ_P O#PQ%
M(OQ,\'--D@Z[IY&1GC[3'T_,^]?ZB7_!-G'_  R_X$V]/[,M<?\ @-!7\?\
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MT/\ C^?K7YWQO*4<IQ/*G%RA).?:\5IIV]%^1R3;?-3ORQC&_/\ S[:?I?\
M%/0_TS?@9#%%X/T3R^<Z9:9_[]1]NW^?:O=:\#^ T4L?@_1?,)/_ !+;/&>P
M\E*]\K_/O//^1GBO>YOWCU^[7^NQ\Y/XGI;78****\@D**** "BBB@ HHHH
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M,H.,KJZ=M.MM'O\ U]YT*U)**5^9^]):)IVTOK_5F11W'F(6(^Z,?ECZ>O\
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M2[C4RAF&#GC/?)]_\GOUJK;Z9#83C48L&=N<=_4 YS_/GC%=5)K;RV+A\"3
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MOOS_ "%>'MPLH68DJ<#'^>*_KN_X.5QFRT[K_P L/YQ?X"OY&_#L;-IT.1P
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MNO\ /W/>;^T\5S?\_'MWT[?(^>E\3MM<****\@D**** "BBB@ HHHH ****
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M6T"_\\8?_0#7^>#_ ,$KK;;\8(WW9S>PG_R(@_S]:_T/_P!FDY\#6A]8H?\
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M_&QK>!;<)XIM'(PGFIG_ +Z /]1Z'U-?W7?\$29('\'#RA@_95SC_=7)_/\
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M_K<^?Q:4:S2CR[:?)"T445\><H4444 %%%% !1110 5%/_J9/]QOY5+44_\
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MYX1CNXMIOJWI_7WCOA^TW_"26K$?/YJ'W^]^'3C_ "*_NY_X(A23/X.7S/\
MGV';&/E'^>]?PN^!X5C\3VDQ V>:F0!U^8?Y'MV%?W4_\$2+F.?P< B@$6J_
MHJY_'O\ XU_*_C35<L)54/>@YJ\NVJT[W[O_ ()Q8^2="R=[+7R>A_1%1117
M\JG@A1110 4444 ?QJ_\'*V/L>F^O[C'US%_@*_DM\.&X?28%<$IMXX[8/\
M@/\ )K^M_P#X.3;-KBQTZ0=%\DG@8X\KU_W3ZU_))X8U.&>PAT]0!*BX)QSP
M/\37]8>"KB\'2<MO/9[+_ACULL:M6YK64;N_;3_@_<1,;A+L*@/EYQT_/^?K
MQ6S.\ZQ_N\\H,XZ].?\ /^-5+NXBM)A&5&22/S/&<'IT_KZU9AU&(@(P!WX
M[]>1Z_3&?;BOZIP-7V512C335U:7:_+IUMTT^>Q[.$@YSC*'P);K;IW^\P7D
ME@?S$XD)&[US^7/.,&K'VV_DC)7<7[#GT_'N/?UP<U>NK/8/M!^ZV#],G/\
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M?\CI[5)7\DRES6TM9?>>-.?-RVBE96TZ[:O^M0HHHJ" HHHH **** "BBB@
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M-QYY8\\CN/3GI7[]X1X/ZQ%U>5*4:C7M>L4K=?Z\O+V<&Y.C9>])36GE9?\
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ML?Y.:^3XEE3GE^.M#VEJ;>GV=.MMNYA4DX5.5Q=525FTG9[)>?\ PQ_IG?\
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M"X7Q!I5WI]LCML>>)XE*\XY8*.WZ54@M+36B"[J48\MP1Z?Y]Z_LM_X+$?\
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M(QQ[_<+T_5+]#^G!/N+_ +J_R%.IJ?<7_=7^0IU?R ?,A1110 4444 %%%%
M!1110 AZ'Z'^5?R0_P#!=R5EU0J!US],$']?Z5_6\>A^A_E7\D/_  7;*_VF
MV>O./ICGG\^XKZ7A*3AG6%:3OS):><HHZ,*FZR2ER:7YMK6:ZG\?NK0HFKW+
M+]XRG./<Y_#D#\:([6)@9<_.1T]\'_ZWTXINIQ3#5[DMDJ9#M]N3W]_?\#C)
MJH6FCDWDD1GC\.V!Z_E^E?Z'<)8><,NHWE[LZ2]U]&XQN]?TOV/J,/)1C-2G
MSRY6E+NW;1JW]?GH&"-E\QB-R\C/&<8/X]?\>*K1L+N0Q2\(OW<G@XZ>WZ\8
MIC&:=@8B=O<#..F?KV[X]L8ITENY4>3P_&<8S]#CTQW_ ,:^MC>,(TY3T@K1
M7?O;Y_\ #+4ZJ4_91I0<=:B??2UM^JNGKVML.NK:-HS&3\N!CICO^N3^=:/P
M_/V3Q?IL<7*FX3)'(Y8>_P#^OCBL6[2?[-M&=^WGGW8_Y-;7PV^7Q7IRS<R&
MX&">OWE]>OOQT.<5\KGW^X8AMV24KW[<JNCSJS47-N#G9WY5_73R/[BO^"-&
MW[%:$'),"$^GW3TX]J_I*'0?0?RK^;+_ ((RP2QVEJS9V^0N >X(8C]/0_\
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M(3@9- "T536]C:7RAUSCC_/^?SQ<H 1AN4CU%9T=@L<QD[D_U)_7_/%:5%
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M_/6M"5&<X5$X2C)J2:M9W/F&FFTU9K="T445%Q!1129%)M*R;LWMY@+1113
M**** "BJDURL; $D=.^![?G_ )[@1RW\<5O+<,0%BC:1CZ!5+'U[#-13DZDI
M1479-*_>Y;IS45+E=GUL?CE_P6;\4R>%_P!GC5+U)/+/V6Y&0VWH@')S[\\5
M_G5^)O%%QXOUR[O'<R_Z5+DY+#&_ZGIZ_EWK^WW_ (+N_'[P_J?P+UGPG87:
M?VC'#=1E%=<YP!]WU)';I7\*?PXC::SO'NQND:>4@MSU+8Z_CZ^N*_J3P<RG
M%K!-RA.FY57)1:UE!I:K39ZGIX-U*<$U%ZR6O1+3]-_^'.XMTVH!Z@9[_P">
MM,D583YB'+$<C/0<9X_R,>QJ65A"6![GC_'U_+I^&*K0QR/(6?E">/S]..<?
MX>M?UGDL)X2C%3IN%-I<R:=K:7_KTN>Q%;S;]VT;K^?:Z7YCHHED/FL0& X'
MN. <?D1_]?-3201N?F/0\<CD9[=L?Y[57=)!.-GW,C/T/;_ZWKZC%0W<=PSH
M4)P ,X/N?3_]0KJG*G4Q47!+EY=;:_R_E;Y:!.4HN,HSW2Y5?X5IIUUU^?7J
M:L5NDZ%6(Q@X_H?IQGGWKZO_ ."<MJH_:F\.I_RS^WVPSVXG3I_G\.M?)"-)
M'!W#;>>>>GK]:^O/^"<DRO\ M.>'D'^M^W6XR.N1.@^O^37YIQZYQRW$<L'9
MJ2YELO=7;M^'XG*_W4JE9Z^T@X?/37Y6\_(_TM?@9!'#X/T78<_\2VTST_YY
M)Z?6O=J\"^ L<R>#M%\TDYTVTQGT\I/\:]]K^ \]O_:F*N^;]X]?/O\ UV/G
M9_$PHHHKR"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_G:_P""]$YA^$73@VDO_H,_^?\ )K^B6OYW_P#@O)$DOPBPV/\
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M.MS*;4I*4EU7HK]%Y?U8;->-%,(\ C/?/Z?EU_*J.H7IMYK8X^\Z>_<>WO\
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M1[?C_A7\)_@01_\ "4VBD_NQ,/I]X?Y_SS_=G_P1'2!?!W[H@_Z*G3_=&?\
M/M7\O>.E>C5P[48-2A9)VTM>/IU1Y69*U*5DTK;/I:R_4_HBHHHK^3#Y\***
M* "BBB@#X8_;*^$%O\0? OB">:%)3!I-W(-R@X\N!^?_ !W_ #TK_-8_:RTE
M/#7[1WBO1D 5+?4+A, <#%S*OX8_SBO]3_XQ0(_PX\7LW\.AZB>W_/K*>_'O
MC_(_RROV\;Y%_:[\<PHPR-5NL=.UU/\ YZ8XS[U_27@#F%LSK8:;]RG&#5[+
M5M?U_5COPTERZ)MQLWOKJM/RU\SQ&XB(F24=%_QZ#_./QK6AO T70$@$^O0#
M!_SG-4'D1[;&09"HP._3'YGG_.*NZ#'&JR"[^7(.W=@'DGZ>_/UR.N/[OS7%
MT*N3T_964XPC&3MUTO?SZ_Y'M4)PTG"$E-NS>MK:7_R^Y==,"\N#)(5"'J1^
M?'^?KGVK1A3?;$9Y/;\Q_GOZ5J36MBLKN2N,G'X\#O\ GGUZBLF N=0 7)ML
M\MVZ^@^OK7R6"I0>'E&2=KREK_->+TTZKMOT.[$I0IT_9OFG>,FEK:5XO3^O
M,N6WA47MC<7#M@HC, 3[?7\3U)Z8K]0?^"2'Q;A^%/Q9S-(L(?48@&)"Y_>1
MKU]<>O7ITK\PM;U>>S,<%B28Y %DV\#D8.<9' _6K7A'QYJOP\\0:/J.C2-'
M<3W]J9"A*DDRKD<>_P! ?Q%?DO&.6JLZ_,DJ=1.Z>R23W^=O7RT//KM\RF[\
M\K.3MZ)7\M_^&/\ 5<_9_P#',7COP18ZQ'(L@FAB.X'(Y1>_?O\ G[<^[@@]
M.:_*3_@E#XSU+Q=^S5X>U+49&>YEL[4G<23DPC/IW[^@-?JA:LY'S_Y&/I]/
M\FOX<SJ@J.98^,6N6&)G%);6NK6UU/ K0E>=1M*\EIU>B+E%&:C#G=[?Y_R:
M\.I6C3<5+>3MZ>;,$F[Z;:DE%%%:IW5UJA!1110 4444 %%%% !1110 5EW]
MV8%P >3CC/K_ )^G;-:E5I[9)\;@.#GG\_\ /^< &/9VC22"X/1B#C]?\_7\
M:VYG,4>1U _E_+Z]J=%&(D"KT%*Z!U*FJC;F7,KQOKZ 4+2[:9R#GJ1Z=#C_
M #T_QTJJQ6R0DL/\_P N<_G4PE0G //^?\_K3K3I<Z4&HW2LF]=D%^Y)1114
M ?B__P %>M)&J_"JXC,?F?Z%-VSCY9..G?\ 3^?^?!\9]$.A>.[FZVE EQ*2
MN .CYX'KQTQWK_2F_P""@?@H^+_A_=6XA,N+.<XVY_@?_P"O^M?YW'[;.CKX
M:^*VH:25\LBXF4(1@C##^'\?0_X_O7A+5=.I1BN;WZJB[;:RC\NU_P#@GLY=
M2J1M5C))3ER?E_7_  ^GS>UZ=6191QY6.W7'Z_\ UAZ&HXI_M1,(&"G'XC\/
M;_\ 75?1U2"+:W 8= ?8\_7T_'K6M%%!&Q>,C+'G!'Z8_P ?\:_N# 5E0PE.
MRUI17,TOBOR[>?WGJ5O;1J17V8/W6K6L[7[W_732Y'#-Y<GDD=\?_7[?S/T[
MTMQ>^5(L8&<X_#J?TQZ_AGBFW 0 ,IS)SP.N<_U'Y5';HDIS-@,.F1WZ=_QZ
MY[^E=]*K!R<JRYE.#DDM[6OKI;^M5T%5I\\?:P33NE)/=O35:[>?^1=D ,1R
M 0RDX],#_P"O^GY?1?[%7C@_#GXO6FM!A'MNH#NS_P!-/ICO7SG)(D:$,<#;
MQD],CG_)-6?"&L'0]=M[Y'V#SHSNS@<.. 1Z_I7P'%U.-7 SC"FU"?,K-?*_
M_#_C>XH.T97W2O\ <NOEOM^1_IG_ + 7Q2/Q,^'5KJ!?>1:P>_1$SS_];]*_
M0EEW?45^&'_!%+Q-_;OP2MKEY=^+2$9)ST2//^'K[9K]R8KF*4X1@3]:_P ]
M.*\,HYUF5-1O3C7DKI:+:WY_UN?-U[NM.5GNGWV2_P B16/W3_G'K4E1/@'C
MKW_SZU(N<#/6OEJ$FFZ4M>79K:VEE_78QZ7^7X(6H4^\/QJ:DP.N.M74IN=2
ME-.RA*[7=73_ $"^_G_FG^@M%%%;B"F%\$C&?\_2GTA4'DBLJJJN*]E+E=U?
MTNO^#IU&K==C,N+4S$,.@_+^GKZ^E<KXUG32/"&OW;.%,&EWD@R<'*02$8S_
M #__ %5W#2*OR@@?Y_'-? '[;'Q[T/X4>"=<CU34HK(W6EW4:"20)N+P.H')
M'//M7JY+@*^,Q5#"P:]I5E&[:T;3B^M[^71['53E5K<M*]HWTNNFFGR_4_AM
M_P""J'[2%WXM^,WBWP(;B1X8KNYC"ER5P)95_I^E?D'I!_L<&'H7;=QQU+$9
M]<]_I7T#^UYK\7C/]H7Q+XFM9?M%K=7T[I*#N4AIY&R#[[N?Z"O!IH?-N8W4
M93*Y]!UX.?KZ=^>E?WAX;Y?/"X7"SJ)7I1ITF[:.RBKW[^KMOHNONT;*BJ;L
M[-)K6[M9:?+_ ()O;C=C?T(&?\X']/RIT5P=WE$8VD_H.OU]JM6_DK& I'W>
M?IQ^'\ZJD1!R5(W<Y[?GZ]?KZU^Q9ABH4Z-E;DLM([K2._W+\>ILG&7-'EDH
MQ5H*STVU=]EO;H_F,:ZQ,$QW]/3 Q_X]^OY2R7(BZKG(/O\ TX_3/X4"!&8.
M?O=O7_'G_P#53W$'\>T'MD^_/?\ S[5Y>!ESU$XR3O%VMT];#<J*<+Q>BM+S
M=M/7RT_S&32D1,0,\'C\,C_#^G:OJ?\ X)O,R?M2>')C_P _]L0#V_?H>2/\
MX]J^9+>.&1#N(VX.,XZ$$#VZ=O8?C]5_\$[( O[47AXJ/D^WV_...)UQ_G%?
M$<<S?]EUZ;:46I+MO%7M_2.5+VM6I3D[4^3FC?9/3=^?]:'^EU\";H7'@_1,
M#IIMI_Z*C]O:O>*^?_@&$'@[1-N,_P!FVF<?]<8Z^@*_@#/HJ.:8I+^=_=_P
M]_ZT7S]:/)4DKIZ[H****\<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU3Y[?P]+=KZ7\SY[%_Q?O+5%%%?D!RA1110 4444 %<?X_&?!GB0?]0B^_\
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MXU6/0=>U"S,<TN/(N)%^Z6_NGC\ACTST_O*^*'_(D:Z<9(LI<?\ ?-?P0?\
M!7.\FCU+6QL)!GF[=B6SZ>V?_P!=?I7 N'688IT9PC*,916J77EO\^O3\#7#
M\SJQBK<DFN?Y/3_@>:/P5T3XU_&BUL!#+XMUEG![WD^>G^\>#V)^N:ZNV^+_
M ,:+NV=%\6:QEEX_TN;.2#_M?C^%<5I%F+N$.4!.3VZ9/?J?Z8KJ[8BQ&& !
M[<<=O4=NU?TKEW!="=%5%AX-M+7D6M[6Z6U/<EA6Y1DDK6Y5I]EV3_3KL<M?
M_$?XYV5P)V\6ZUL#AN;R?U''WNO7^A]/W3_X(L_&SQ_X@^/6CZ-KGB"_O(_M
M%LK1S7,CC!+#&&;H>_;CZU^+U[Y=_:REE'R(Q' XX_3IW_'FOT"_X(K^(Y+3
M]KS3K24E(5O;9<DD+_K)!WZ=OP/I7PW&_!=&A@L755*U2A2=1*,=+J*M;^O*
MQ&,C2I4(4J"]Z#O)NSW\^ZV/],O2=QT^S9CDFVB)/<DHIS6E6-H-W#=:58/"
MZN/LD'W2#UC4]JV:_E^:<924DTTWHU8\&X4445(!1110 5#(V"/\\^O\JFJ&
M1<GGZ_TQ7%C_ &OL/W7Q<T?NNBHVOK\O4D5LCW'6OQH_X+61/+^RSXB"'!^Q
MW?\ Z)'^/\Z_9-2%W,>  23Z5^*?_!:GQ+IJ_LQ^(;2.ZB-S]DNAY8D7=S$!
MTSGJ,=/YU]!PG[:MF>6R47*<<32;LKVUBW?TUU-*:_?1MLI+_@G^<7HZ21:C
MK$3$EFO;D#M_RT;OU[?KWYKK["UFC)9R<-G\^G^?_P!=<MHH>;4M7ED4@B]N
M2..?]82!Z]#_ "'-=M:S%B5?Y0IX_ ]_Q_EZ]?\ 17A+#5Y8"$G\4HP=K[.T
M;:-(^CIJI*'.]8P<>7:]G;3]?09)!)"_G$_+DG'X?E0L<ERPD4G:.HSQQUZ?
MY_6EDF>=O)(.T'!./7C^6*A$TMJ_E*#@^W;\/\<GU'6OIZE2=&-Y_P 166G\
MNB[[GJ15-M6NI^RVMLK*_H_ZVL:("HO Y'?VKE=656GME;C-Q'S@?WAW/^>:
MWVF;CKSQ_3I[]_Q_'BO'EQ-8VUG-:J7D,\9PO)X91R ?\X_ ?&<58FG4R_63
MLT[N^^BOKIVZ:=?7R77C&52#3YN_2S:MKTMYG]W7_!$WP]-)\']'N4!V+#:L
M2!A>F?\ )_PK^E?3HVCMH%/\,8_ET^M?S\?\$$[.74OV;M+O;J,K*+:VX<<_
M<)[C(_'_ /5_0JB[$5?[H K^%.-,;#$YK6IT]51FXW>^G_#+?_,\3%SIN25-
MMO[=]5?3;^K;CJ***^..,**** "BBB@#^2C_ (.,#CP[:?[D?ZA/\*_C<TR%
MUA#D_+R1^5?V1_\ !Q@,^';3_<C_ $"?X_E7\;NF3,T(0YQSC^0_#\LGCBOZ
MC\%N=X>E[-QYDU>]K?9_"V]SW\#S^PCRVWUOOTV_'?H69(V\P2?P#&1].?I[
M<_X9D\LW?^JXVYSC^??T['/8U3GGD$@B ^4GW_G[?YXQ5N*3[+C9SNZC]/;/
MH0?_ *U?USA?;2C3I5+*=2/NM;6LO1=?2QZM&I"<ES+6'P]FM-[==$Q\T+[!
M&"<\?7@C/^?7/>I+2)CB(Y)8@?@>/ZC'\^])=3,(Q(,Y(#?F<_I_//UJ.RG8
M,)2"""/TQS_GGCUKRL?.IAXNE9-N6_EIMV?IJ0E*5-WMR<_2U[Z:WU[+8M:=
M9-!XMT8'O=PCCCJP]OI7]JG_  1UM94;17)R"MOUS_=C'\S7\5>GWIN/%NC$
M_P -W#TY_B_^N.M?VJ_\$=;N21M%0CA4M^W7Y8SR?P_E7\_>+7M/[(Q%K6]F
M^:^_2UK^=OO=]#AQW+['97\M_B27Z?+YG]12?<7_ '5_D*=34^XO^ZO\A3J_
MCD^<"BBB@ HHHH **** "BBB@!#T/T/\J_D9_P""\(+:H5'7G^8_PK^N8]#]
M#_*OY&?^"\)VZH6&<\_H1_CS[5]/PA_R/,)_CC_Z5$TI?&OZZH_C^OK.6/5K
MEV)*F0XSG'4_G_\ K[5 \31N)3_J^/\ ]?IQ^=3WU[))JUPC A5D.,CW)JO)
M*SMY1^YZ]NF>O(ZCTZ=Z_P!&.&6EEV';O94:;^?+&^_I_5V?18%2=.RY>EV]
M^73O]JW_  "586NR'C.%'!'KP?PSU'7%6XT*_*."!S[_ .?ISUJE',UHVU 2
MIY)]\?7M_7Z4^:X90&3))Z\G/KV/M_2O9J6JU*3=U&6]KKM^7GWV.^M#FC1C
M2;U5EWZ:?/\ 4LOG!SU_^O6WX$A5_%NF+CYC<+CTR"/QZGC^E<^CL\9+ Y(!
MQW&?\\_B:Z'P)*$\6Z8V?F$ZD?4E?Q[?S]#7QO%?(L!B$N;G496MVY5O]QP5
MTU3:>K4M7O\ R_UI^1_;Q_P1GM)8;2U9V)!@7&<X^Z3C_/\ .OZ3!T'T'\J_
MFS_X(SWDL]I:HX.! N,CIPP__57])@Z#Z#^5?Y^\5_\ (ZQ7^(^<J?$_^!^@
MM%%%?-D!1110 4444 %%%% !44_^ID_W&_E4M13_ .ID_P!QOY4UNO5?F!_&
M-_P6YD'_  FNH1_Q&2<#ZGS".?QZ_A]/Y26MY8=5OF<Y#RN1R?4]J_JW_P""
MV\0_X3>_D'WA).?R\SMZ^@X]<U_*A/,TFIWBD8"S.!Q[GJ>/\D<#-?UWX.RJ
M?5L*HVYN6/)MIMOZ_EYGN82G4E&G.27+&UK+5_Y]+O\ X<A*M#(96/RDYZ>I
M&,?R&>WK4\<$ERPE4_(#R.WI]#Z_CQBH-S3.8B/ESP?H>/\ /\NUFVF>"40
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M44E?36ROO;SU7^9HG54JK:C>RYMNC6UNJMU+:J25;.!Q]>/_ -7K5&ZM99I
MR' '/?U]J5KAEF"+G;Z]CGOZ?_6Z&IIKB2,@ =>H ]/7_)QZ5EEL%1E;6_+[
MWJ[;?-_TC.5&3<5I[UG'R2LU\_ZN/572#;GD#GWXQS^//_UZ^NO^"<<ZR_M/
M>';?J_V^W^O^O7'_ -8]/SKY"G=_)8J#G:>WMGG [<_3WKZA_P"";\CI^U-X
M<DYW?;K<XYX(N$/X>Y_2OC..:5.IEF(>OM$I<K7HK-_AK\N]N*O423IZJ45=
MN/79_P!?\.?Z9WP&M6M_!^B[CG.FVG_HI/UYKWRO!O@3</-X.T/<.FF6F/\
MOTA_/U^GY>\U_ .?*2S3%<V_M'M_7:QX$_B?Z^@4445XQ(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?SP_\%XD1_A'ANOV
M27]%G/\ C_\ 6[_T/5_/%_P7A7=\(\G_ )])A_X[-_GT]>M?4<&<W^L>6\JO
M+VRLN^J-\,[5H.[C[RU6ZU6Q_!IJ@CBU:0G&WS6Z@X//Y^G^>E*ZN0\\0B/R
M@C</;/Y=Q_\ 7JYK4?G:I*F<$R-_/_$?TK*>U-M/&N<[N/;M7^@_#E&G4PU)
M)^]R1<]7[LM--;?TKW/M<+9T6Y13>EF[;:6O?\M/P1TS%3;I@<X&>Y]_?'^<
M5E*UOYQ7'S[CSC]3QSS_ )XYU!'Y<*G/4=/0D>]9(L3YYN-W?_Z_\R:^H5*,
MXS;DXU(JW+%NUE9+^OGOOY]=R]H^:*C?HMDK+^NR^9.XAW@N!NR,$CWK/OGM
MQ/;^9C_6)CCW7MBKLMN7D#[L8(_GZ8_KS69J5F;B:V&<;9$S^8KF7+RW3;?)
M*Z>R]U7M?MZ^@24%&+BVY/XNRV_X;I]VA_1'_P $4\GXNZ1L^[Y]MC''=?I_
M^L5_>C9?\>=M_P!<8_\ T$5_!=_P10_<_%S2$ZD3VP_4#^O_ .NO[T;+_CSM
MO^N,?_H(K^#O&;E_UJGRR<ER/Y:[?U\CYW%_Q?Z\BU1117Y$<H4444 %%%%
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M_6O(QRM3K1;;44EKVO'J9Q5M$K63LDNJ7]/U/TM_X)9RP-\7XU3&X7T.>/\
M;3^F!TSVYK_0\_9G!'@:TSU\B#_T!O2O\[S_ ()76)C^,D<A;K>P''_ T'^1
M7^B-^S4<^!K,X_Y8P_\ H!/]:_D'QBIKZO&=VFZZ]W6W37Y]=KH\O%R;I.[;
MM-[^L=CZ/HHHK^>#R@HHHH **** "BBB@ HHHH S-8(_LV[W=/*;^1K^3?\
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MO]=;;:&5=WLY-^T?Q1W25E;]?^&U-SP'<K)XHM"3F/SEXZ_Q+ZU_=E_P1(:
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M,#U'IDG/3':OX[S+)JN68NKAL7"4>6\J;M>Z37*_GN>).$H.TEKI]SM^CO\
M@=0#D9%+34X50.1BG$X!/I7C/=^I(451-R1+Y9S]?ICMT_SCWJR\T<:%Y&"
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M# .>]7)YI0XCP1'R#Z=<=<?X<=*DBFBW[,?..N.N>O/?)(. ??\ !+J9#^[
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M#N:4VXK"5'&GO.SUVWO;;^K=<:RLXP4;.":;L[O;\O/78_<"BO*/A5\2]/\
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M_5+3?\3^936-+@BFEMYE FMW*LI&"&5L8/XY^@'6N8B>1)2G(1<[?3&,=O\
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MC9?\>=M_UQC_ /017\%__!$[CXM:0),;O/MLY]<C_P"M7]Z%E_QYVW_7&/\
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MMM*%I-*+J18SMC9@0S!>P/K]/3J*Y[PQX<\3_$;65\.Z8DT\;2A%C4,1@L0
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M3+D*9#CMW/3_  ^E0L7+@L3Y7?/3I^7'OWK_ $9X9TRZA+EO:A3^]0CKI?\
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MD]G:VGK_ %IN:IT&TLD\^,J6;GC!Y_7T'MWJG<NL499 -V<#'\__ *_3%0V
MU"3*SEMHZ<G@8 '^>M2R6\@FS*"8A^74=<_3/'TQFOH:&"@Y0O3Y>7E]+JW^
M6GS9DJ=27-NN576EK]?O?^=NPZQF$Z$N-IZXZ=?3\!T[^E:,<<;[M[  ' R0
M/QY_QYK!EE6.0"(X7/..F/S'_P"L&B\GE=!Y#'/?&<?I_P#6]J[<5"FI12I\
MT/M)=;6M\]K>MM28TY4N2I-<T7:\;;;;Z7U^6]A-;MH[J+RE/&?SQG@=O;_"
MOT/_ ."<?BPZ!\:/!NE++@2:C;+C=_TVC'3(_P GI7YSVT=S+Q)DGD]"<?\
MU_\ /;CZ-_8KUBXL?VG_  ):;RJMJMJ",GO/&.GKR.W8?C^-^(,*=/ 8N32O
M[&=K=%R;=]^IGF$'['DIU$I2M.W7ET?*^_K_ )'^I5\()C/\.O"LW7?I-FWY
MPJ:]+KR/X%N9/A5X,<\[M$LC_P"0$KUROX/K_P :K_CE^9\L]WZA3'7>I7UI
M]("#TYK&Z32;5WLNK$9L%@(I3+W)_GC/^?\ (T_?'-)D4M":>J=T!\X?M*^
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M:U).=E"/+"UHJW6RUU]%ZEPFUR)WE&+O;OI_7WFEHB+'HDR-@L4[]>G;_/\
M]?G--BVW$^.0S,/7&<]/3KCV_&M%YS IME.W=Q@=^W]?3';Z5X%-J2T@QNY'
M&,D\_P#UR*[<!1;C4JMVE2TVUUM_7Z=#:4+PJ2]FU*ZY%UMH_GL_DR>ZMEMO
MWXQDC/4'/ X[]?Y=\5SP=I[@-C@L.W'4>W8=:W;^?S(1@Y&,>GK^H_R:CLK5
M1%YQ7ISG'8?Y]"/RQ668855Z<>>'/'F3U2[K3UMK^/F:ODE2C*K1;G&T8I[I
MNVOX?\,Q'\,VFJ('E=495!&2!T&0.N?3/4>^.CK+PS&S-$),HG0YR.!C&<=?
MI63J$]^\Z"R9M@8!L$_3^GO^'?H[6ZEMK=#(<.P.[/<XY_\ K^]<^'RG".E+
MFI)72Y;K9Z/3Y?=\CAJ4$N2I*-YU':UM>EK^?4Y.ZL#;ZB+?+,F<9Y(ZC^?K
MZ"NDCNUL4%LN-L@VG'J1V]_7WI\Z)=?OE \PGJ.OZ>AQWQ6-+9W+99E.5Y'T
M''Z]_P!36E/+<#15W"#E?X]/=O\ UKY:Z&N$PT')U.72"UAUTM]WWW^9HMI,
M+'SU(S)R<'D=CG\SGOU_"V=.@6+<77=QZ9SQG\.W''YUBVL\\+%)B<=!G/\
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MY8WBGUVT_IZ&C+((T)S\WIQSWZ=>G^>]4XK5;_>9" >< G\1SU^G%5)%FFN
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4:$'+6_)97UU2U\UKL9P)M7RW.6'U]/3'.?3'7US5JXG,40E &" <8]>0/\
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M1GIZ]./7\?SIUS>?,8,9R>O?GO\ SJ&*&-'\U<;SSUSU]?P_E]*D9;=I0S,
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M_'/_  09\+:"9KBVMD)0.^5BY]>R\]/T[U^RY+XFX*IRT:=>2E=+72RTW?\
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M:HVC'XTZB#DX1<E:32ND!5N=VT[>N!_,Y_SZXHMMVT;NN#_,8_SZYJR0#U%
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M3D8C3KQCMZBO9**7]HXUJSQ%5KLY/R\_+\Q^UJ_SR^\S--TNVTN 06Z*J#@
M ?X#_.:6<2;UVC@'_.?Q/\_:M*D*@\D5RJI+F<G[S=[WZWW"%1PES-<SUW\Q
MD>=HS_G@5)114MW;?=D-W;?=AG]>E%-9=Q!S3JRA*;E-2C9)VCYZ(0P;MW?'
M/TQV_P ]?UI]&:,YZ4Z<.1/5RO)O7Y: %%%%6 4444 %%%% !1110 49_7I1
M3'4GGT'2LZLI1C>*N[J_DKZ_@ ^C/;O4?F>W^?RIJ_>'X_R-8/%1;A&'O.4D
MI>6JO_6H^5VOT_SM_F3'.#CKVIB;N<Y]LT^BMY0YIQG=KEZ='_7^0@HHHK0
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M110 A&>"*7IP***7+'FYK+FVOUL 4444P"BBB@ HHHH **** "BBB@ HHHH
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M*@PHQ6WM(^RY.5.3?Q=M%^=K^OW@/HHHK$ HHHH **** "BBB@ J-R<@#O\
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MZ +135SCG/7O2+NYSG\?Z5DJUW37*_?_  _X']=!VWVT_'T[CZ***V$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444P;MW?'/
MTQV_SU_6LYSY'%<K?-*VG38!]%%%: %%%% !1110 4444 %%%% !1110 444
M4 -9=V/:G445*A%2<DM9;L+A1115 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %1NI/(].:DHJ*D%4CROU3[,:;6Q
M#RV !T]/ZTY#_#CG_/6G@ =!1@9SCFN:%"I%QE=<W-[_ &<=+6\_\O,+_P#
M]=+_ *BT445V""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140029588278208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 29,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MD]K Q_RG2,]^(36*M-VF+8RM[!,>;N_Y+ Y@%7D>!1?HT#8&4K8%#_?T3S*
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ %XR^6&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( !>,OEA]*'$5[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !>,OEB97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ %XR^6.9"?/I9!   F!   !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !>,OEB?H!OPL0(
M .(,   -              "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20029730x2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>insm-20240529.xsd</File>
    <File>insm-20240529_lab.xml</File>
    <File>insm-20240529_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ny20029730x2_8k.htm">ny20029730x2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ny20029730x2_8k.htm": {
   "nsprefix": "insm",
   "nsuri": "http://insmed.com/20240529",
   "dts": {
    "schema": {
     "local": [
      "insm-20240529.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20240529_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20240529_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ny20029730x2_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://insmed.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240529to20240529",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20029730x2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240529to20240529",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20029730x2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001140361-24-028205-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-028205-xbrl.zip
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M/&BZ;MM'4'MLMQ0J"^(F5-KZL;^@JQNQ2C*\ZZ"(U0V(-@B\LUSM8+?3#.A
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M7_^29T"Q12MQJ=4Z0]HR"G=B]0',^.KZ"9:9'<F"'I'=5EOR@A) S&NZR O
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MPC$_('YROH^(/^(GVI_^!U!+ P04    "  7C+Y8"PG](]$5  #D>   $P
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MZ*+7YMW))5O0,!'*C8MM=>+]8^YPYZH;SSWN"A!N6J% !'>UN H-["MF(.$
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M*,AY-@^O$N,0,SSE++54E2QVP0WCFB.3LP\'R"JX!\5K__K\^9NPO:\R1XD
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MPENQ/!$@.!L'4\(+V?.I"KU]:DO(AM,SG<H>]+^S_+'H9@>I;7OT<M,Y;#R
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MA/P@I#,=S.@^@-)+9)>*+BNYX,[6><-3_R(S XQF://$* %&NZ&\JC<SKN^
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MK\F[+*];SL/U>6P>(.>N9J$V'/J7Y>\J]YZ><@#2HY9NI7<<FYJ.V9  P$:
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MAUD535Y-#?WJQ4^CR%O1BVDZ"^#%_P-02P,$%     @ %XR^6"F2HUVQ#0
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MMV\4278E+J2M"C8UR[K@TW3B%P/C!,29JZ&MB\+KL9 +&CDG-=VDG=N![)8
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M4L6IA&%C6#-$L$8$CON'<&ND'6'B4'ZD8D+4MN@Q/@:[;R@);"2M[/9'QT:
M'(= )H;QA#G!!J)SPBA_A$20UHJI=K4^PKLBBY*,<BBM !=4"(-I%DOR\0^Q
MM=%O/$+X%(Y_$*:0BVVTRX=@BE>DGLN8J/E/LN+/$$*I^(@4A,L+O:VT.:</
MY?;JVI9(^'PSPRWP1&@9@>5*=$QU>4<#<<U)$29-QV>[XNG&'/ 3DS.J=-#P
MT7(IWR/+R\V<\J((1A<P;^;G"64M(CBH-X9!]#SCFAV=A4KQ>W<+=(W( J0
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M;<F[#?\Z-G 1%MJ0C\69^VWA/9!@>6>A;I0>1 _:V!_/B_="<H"0SA+*;2*
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M,#(T,#4R.5]L86(N>&UL4$L! A0#%     @ %XR^6(Z,EG[:!0  [3X  !4
M             ( !'@P  &EN<VTM,C R-# U,CE?<')E+GAM;%!+ 0(4 Q0
M   ( !>,OE@+"?TCT14  .1X   3              "  2L2  !N>3(P,#(Y
M-S,P>#)?.&LN:'1M4$L! A0#%     @ %XR^6+WWNA0WD@  7"@# !8
M         ( !+2@  &YY,C P,CDW,S!X,E]E>#$M,2YH=&U02P$"% ,4
M"  7C+Y8*9*C7;$-  #K0   %@              @ &8N@  ;GDR,# R.3<S
M,'@R7V5X-2TQ+FAT;5!+ 0(4 Q0    ( !>,OEB?8*O0PA<  &Q/   7
M          "  7W(  !N>3(P,#(Y-S,P>#)?97@Y.2TQ+FAT;5!+ 0(4 Q0
M   ( !>,OECC@)IR-!D  (M4   7              "  73@  !N>3(P,#(Y
F-S,P>#)?97@Y.2TR+FAT;5!+!08     "  ( !@"  #=^0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>ny20029730x2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20240529.xsd" xlink:type="simple"/>
    <context id="c20240529to20240529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240529to20240529"
      id="Fact_c8dda05d303c4b779810a738c71c9361">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240529to20240529"
      id="Fact_de04b2cd7eda43e5957508693291fcc5">0001104506</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20240529to20240529"
      id="Fact_eae7af90ccef4de6b9fc813a666f75d5">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240529to20240529"
      id="Fact_5253ef384f724a11833ad67cc37b3491">2024-05-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240529to20240529"
      id="Fact_33384b1a15c94797a165d1d61baeb201">INSMED INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240529to20240529"
      id="Fact_764567eb4bac4d22a41cf6e79c04d22f">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240529to20240529"
      id="Fact_479c213e4fb64cf989e8c030be0f9f59">000-30739</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240529to20240529"
      id="Fact_eaf62598e30040a3b31def86ccaed95d">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240529to20240529"
      id="Fact_304ae780e41b46c78f1709c138914032">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240529to20240529"
      id="Fact_f5662e85d14e40ebb636a9fda667489b">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240529to20240529"
      id="Fact_47da7fabba374f9da8d2c6a142d6086e">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240529to20240529"
      id="Fact_e26b09d7cee4496286fae9e011b89948">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240529to20240529"
      id="Fact_b297373456414a0dad9df941da58dfee">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240529to20240529"
      id="Fact_ab67c0cb465c436b96230368a22140ef">977-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240529to20240529"
      id="Fact_53d49ec961ec4869b7317396708aea19">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240529to20240529"
      id="Fact_e0e1678cfd89425394a5c5cc88306f6b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240529to20240529"
      id="Fact_757f68c5b374477a9c977602de2cee53">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240529to20240529"
      id="Fact_2a79e5018113423ebdd403ab96e9d660">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240529to20240529"
      id="Fact_b44f21f76eee41db9260f6bbadbeff0f">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240529to20240529"
      id="Fact_c17e9219d6664984a715939b46221d49">INSM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240529to20240529"
      id="Fact_f87e91fe3f9842a4a1cdd8ce052ef785">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240529to20240529"
      id="Fact_6cabafac55704fcf82f9816de9e91a1b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
